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CHAPTER I 
 
INTRODUCTION 
 
Clostridium sordellii 
 
 Clostridium sordellii is a Gram positive, spore-forming anaerobic bacterium that is 
present in the environment, commonly found in the soil, and capable of causing 
infections in humans and livestock (1). C. sordellii was first characterized in 1922 by 
Alfredo Sordelli and was named Bacillus oedematis sporogens (2). Other early work 
identified it separately as C. oedematoides (1) before it was realized they were the 
same bacterium and the name was changed to C. sordellii. Some initially considered it 
to be a pathogenic form of C. bifermentans (3); there is high similarity between the 
bacteria except for the additional virulence factors expressed by C. sordellii. The 
bacteria produce two large exotoxins, TcsH and TcsL, which are the major virulence 
factors of infection (4–7). 
 
Clostridium sordellii infection 
 
Epidemiology 
 When C. sordellii was originally isolated and identified, it was seen in patients 
who suffered from gas gangrene and was thought to be a disease of war (3). During the 
world wars, a higher incidence of gas gangrene was seen in wounded or post-operative 
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soldiers, and it was noted that the longer it took for a wound to be dressed in the field, 
the higher the risk of infection due to increased exposure to the environment (8). Gas 
gangrenous infections were also seen at the site of surgeries during post-operative 
recovery of patients (1). Although the incidence of C. sordellii infections is relatively low, 
the severity of infection and high rate of mortality makes infection important (2). 
 Another frequent source of C. sordellii infection is in post-partum females. 
Women who have natural childbirth and those who undergo spontaneous abortions can 
develop C. sordellii infection. Several case studies report women experiencing 
abdominal pain and swelling that can progress to weakness nausea, vomiting, and 
diarrhea (9, 10). Often the cases are thought to be a result of giving birth or operative 
birth so the doctors do not look for C. sordellii infection specifically when addressing the 
symptoms. By the time bloodwork positively identifies C. sordellii, the infection is often 
severe and the patient can quickly succumb to toxic shock syndrome-like conditions in a 
matter of a few hours or several days (2, 9, 10). It is not fully understood how the 
bacteria are able to enter the patient and cause infection, although some reports 
indicate clostridial species present in up to 18% of normal vaginal flora, and C. sordellii 
may be present long-term in the vaginal tract of up to 10% of women (2, 11, 12). Fecal 
contamination that enters the vaginal tract during childbirth is another source of possible 
infection. It is thought that the bacteria are able to enter the host through tears in the 
vaginal tissue or by directly accessing the cervix (2). 
 A major outbreak of C. sordellii infection was seen in women who underwent 
medically-induced abortions.  Two drugs, mifepristone and misoprostol, are given orally 
to induce abortion, however many providers gave the drugs directly into the uterus. In 
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these patients, an increased occurrence of C. sordellii was seen (2, 13, 14). The 
symptoms reported in case studies are similar to those for postpartum females, with 
patients complaining of abdominal pain, weakness, and swelling, which despite 
treatment with antibiotics often leads to death (13, 14). As a result of the increase in 
infections, the United States Food and Drug Administration (USFDA) released a public 
health advisory in 2005 suggesting a possible link between the use of these two drugs 
and C. sordellii infections (15), and literature provided to health care providers offering 
abortions discusses the role of the drugs in deaths associated with C. sordellii (11). It 
was later shown that intrauterine injections of misoprostol in rats leads to increased 
mortality from C. sordellii due to a decreased macrophage and TNF-α response (16). 
After the USFDA advisory, the prevalence of mifepristone and misoprostol use has 
declined and so has the incidence of infection associated with medically induced 
abortions. 
 C. sordellii infections are also seen among injection drug users (17–20). Injection 
drug users, such as black tar heroin users, have been seen to develop infections in soft 
tissue at the site of drug injection. Drugs, particularly those cut with dirt as is seen in 
black tar heroin, are thought to become contaminated with C. sordellii spores that are 
then directly injected into the patients. The presence of C. sordellii on drug 
paraphernalia gathered from the homes of several patients has been observed (19). It is 
thought that the spores are able to germinate in the anaerobic conditions present at the 
site of injection and lead to infection. This was evident in one outbreak of C. sordellii 
infection that was documented in the San Francisco Bay area in the late 1990s and 
early 2000s resulting in a cluster of seven cases (18, 19). Around that same time, 
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Kimura documented the presentation of nine particular cases in Ventura County, near 
Los Angeles, CA that was also associated with black tar heroin use (20). The patients 
were noted to have used “skin popping” to inject the heroin subcutaneously, and the 
infections and necrosis were seen at these sites. 
 Infants have also been found to have C. sordellii infections. Shortly after birth, six 
neonatal patients were identified as having C. sordellii-associated necrotizing 
omphalitis, an infection of the remnant umbilical cord at the navel (21). The babies were 
seen to have gastrointestinal issues and were irritable at the early stages of infection, 
which then progressed to edema, tissue necrosis and thickening of the abdominal wall. 
While one infant survived following rapid and aggressive surgery to remove the infected 
tissue, the remaining five died within four days of initial onset and diagnosis. In each 
case it was suspected that the infection was a result of direct transmission from the 
mother based upon the presence of bacteria in umbilical discharge and the mother’s 
vagina (21). 
 C. sordellii infections may also occur, although extremely rare, due to general 
trauma or injuries which break the skin and allow for bacteria and spores to enter the 
tissue and grow in an anaerobic environment. One report is made of a 4.5 year old girl 
who developed swelling and pain in her big toe after jamming it on a door (22). The 
initial injury had caused minor bleeding at the toe nail and it is believed that the injury 
allowed C. sordellii entrance into the patient where the infection progressed. The patient 
suffered edema in her leg and lost the toenail at the site of infection but was able to 
survive after debridement and intensive use of antibiotics. This case was the first noted 
survival of a patient after soft tissue infection, and is most likely due to aggressive 
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treatment as well as the patient’s ability to develop antibodies for the toxins produced 
(22). Another case was reported of an 81-year old woman who was found to have C. 
sordellii infection (23). This particular patient was seen to have necrosis which was 
focused around the anus and erythema extending from the genitals to the buttocks and 
lower back after a self-induced break in the skin lead to development of C. sordellii 
infection and sepsis. The patient died after deterioration of her symptoms despite 
aggressive treatment with antibiotics (23). 
 Although extremely rare, there has been one report in the literature of a patient 
becoming infected with C. sordellii following a tissue allograft. The 23-year old patient 
had undergone knee surgery and musculoskeletal tissue was obtained from a cadaver. 
The patient presented with symptoms similar to C. sordellii infection and blood culture 
tested positive. The patient rapidly succumbed to the infection and spurred the 
investigation of Clostridium infections in tissue allografts (24). 
 
Symptoms 
 C. sordellii infections are often difficult to diagnose due to the fact that the 
symptoms are often very non-specific, can be similar to symptoms of other insults, and 
are varied across different infection sites. Because C. sordellii infections have a low 
prevalence, doctors do not initially suspect it as the cause of patient symptoms. Often, 
initial infection will present itself as a mild rash or sensitivity at the site of infection and 
can be accompanied by weakness and leukocytosis, an elevated white blood cell count. 
One of the hallmarks of C. sordellii infection is the lack of an elevated body temperature, 
which masks the presence of a bacterial infection to health care providers (2). 
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 As the infection persists and worsens, the patient’s symptoms will become more 
severe and mimic those of toxic shock syndrome. The patient will begin to display 
hypotension and tachycardia, an elevated heart rate (2). Typically the development of 
more severe symptoms prompt health care providers to become more aggressive with 
treatment and the use of antibiotics. Further investigation can reveal the presence of 
necrotizing fasciitis and edema. Bloodwork may also reveal the patient to have reduced 
serum protein levels and elevated hematocrit. The infection will progress rapidly into 
fluid secretion as the capillaries become leaky and multi-organ failure occurs. 
The lack of effective treatment means that the infection often ends in rapid death 
in a matter of hours or days after patients initially display symptoms and begin treatment 
at the hospital. Those patients who develop a fever early in the infection have been 
shown to have a higher rate of survival (2), likely because doctors will pursue a specific 
diagnosis and treatment earlier preventing as much damage to the infected patient. 
Those patients who are identified as injection drug users are also more likely to survive 
infection because the doctors are quicker to suspect C. sordellii as the cause of 
infection. In contrast, a post-partum female or those who have undergone trauma may 
experience symptoms such as tenderness and weakness due to a variety of reasons 
associated with childbirth or surgery related to the trauma. 
 
Treatment 
 Unfortunately, there is not an established effective treatment course for C. 
sordellii infection. In-depth studies and analysis of successful therapeutics have not 
been done due to the low frequency of infections as well as the quick onset of a high 
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rate of mortality (2). Early work to understand the gas gangrene infections seen on the 
battlefield indicates that these infections were given the highest priority upon diagnosis 
and that the best course of treatment was immediate debridement at the site of 
infection, treatment for septic shock, and supportive care (8, 25). To date, the best 
course of treatment is to start the patient on intravenous antibiotics as soon as infection 
is identified. Original studies suggest that C. sordellii is susceptible to penicillin, 
tetracycline, erythromycin, clindamycin, chloramphenicol, augmentin, and metronidazole 
(8, 26). Although more recent research indicates some antibiotic resistance may be 
present among various strains of C. sordellii (27), the use of antibiotics is still one of the 
only methods of treatment. 
 Along with antibiotics, debridement can increase the survival rate of infected 
patients. Emergency surgery allows the health-care provider to identify the area of 
tissue necrosis and to remove the dead tissue that contains high levels of both the C. 
sordellii bacteria and the toxins produced during infection (20)(25). Because C. sordellii 
infection is a toxin driven disease, after the bacteria have produced toxin and those 
toxins have begun to disseminate through the body, very little can be done. The use of 
antitoxin to prevent intoxication in animal models has suggested that treating with an 
antitoxin may have a protective effect, although the use of antitoxin in patients was 
discontinued in 1943 due to a lack of value seen during treatment (4, 7, 25). 
 
Disease in livestock 
 Not only is C. sordellii responsible for serious infections in humans, it can also 
cause disease during infections in livestock. C. sordellii has been implicated in causing 
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gastrointestinal disease and gas gangrene in sheep and cows (4). The bacteria are also 
seen in horses, and as a result, many horses are given antitoxin vaccines to prevent 
disease (28, 29). 
 Infections of C. sordellii have been identified in the umbilical remnants of young 
foals. The infections present as omphalitis of the infected internal umbilical remnant and 
leads to the death of the foals (30). The tissue surrounding the navel was red and 
swelling was present along with cloudy, bloody liquid. Examination of the animals 
showed damage of the vasculature present in the umbilical remnant and hemorrhaging 
was present in the abdominal organs surrounding the navel. It is believed that the foals 
became infected through tears in the umbilical cord during birth, and C. sordellii 
intoxication and septicemia led to a fatal outcome in each case (30). 
 There have also been reports of C. sordellii infections in sheep and lambs. One 
study from Norway showed that C. sordellii was responsible for some cases of 
abomasal bloat, swelling of the fourth stomach in ruminant livestock. Out of 41 lambs 
that were tested for abomasal bloat, 8 (20%) tested positive for the presence of C. 
sordellii while no lambs lacking symptoms of abomasal bloat tested positive (31). The 
sheep who tested positive for C. sordellii were also more likely to show symptoms of 
hemorrhaging and ulcers along with the gaseous distension of abomasal bloat. Another 
case out of Argentina supports the idea that contamination from environmental sources 
into needle puncture or wound sites can allow for infection (32). One sheep became 
infected after a blood sample was taken without prior sterilization of the puncture site 
and the bedding environment was found to be unsanitary. The resulting C. sordellii 
infection lead to death of the sheep the morning after the procedure, and the body was 
 9 
found to contain necrotizing fasciitis, severe edema, and hemorrhaging caused by the 
release of toxins around the location where the blood was drawn (32).  
 Interestingly, not all cases in livestock are infections of soft tissue but can be 
gastrointestinal infections instead. One report tells of a horse who was experiencing 
abdominal discomfort and depression after importation from Holland (33). The 
symptoms progressed to increased abdominal discomfort, depression, agitation, and 
neurologic symptoms that seemed consistent with encephalopathy. Examination 
revealed a gas-distended colon and an increased ammonia level in the blood, among 
other symptoms. Aggressive treatment led to the lessening of severe symptoms after 
four days, and the horse experienced several cases of watery diarrhea. Fecal samples 
revealed large quantities of C. sordellii present, which was suspected as the cause of 
disease due to the fact that C. sordellii produces a urease which can break down 
proteins and cause a buildup of ammonia, as was seen in this incident. The 
veterinarians suspected that the disruption and stress of importation upon the 
gastrointestinal tract allowed the bacteria to overgrow and lead to the infection and 
symptoms (33). 
 Interestingly, there has also been a recent report of C. sordellii infection in 
captive lions. A zoo in Spain had five adult lions die after developing depression, 
lethargy and loss of appetite and treatment with intravenous fluids and antibiotics was 
unsuccessful (34). After testing for infectious diseases and parasites, only C. sordellii 
was found in the infected lions. The cause of the infection was traced to contaminated 
water available only to the infected lions, and no other animals were affected (34). This 
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case shows the importance of the environmental presence of C. sordellii and spores 
that can lead to infection in animals upon ingestion. 
 
Clostridium sordellii virulence factors 
 
Pathogenicity locus and genetics 
 The gene for TcsL expression was first published in 1995 by making probes for 
the repetitive C terminus based on the sequence of the TcdB, a toxin from C. difficile 
which has been shown to be biologically and immunologically similar to TcsL (35). The 
sequence for TcsL supported the high homology to TcdB of C. difficile (76%) and also 
indicated the presence of a hydrophobic region between amino acids 980 and 1045 as 
well as the presence of four conserved cysteines between TcsL and TcdB, suggesting 
possible mechanistic roles for these amino acids (35). 
 The genomes of two strains of C. sordellii have been sequenced and analyzed 
(36). The work was able to identify a pathogenicity locus that shared many similarities to 
those seen in other Clostridium species, particularly C. difficile (36). The gene for TcsL 
was identified in the pathogenicity locus based on the previously identified sequence 
and was conserved between the two strains sequenced. Located just downstream of 
tcsL is the tcsE gene which is thought to encode a holin-like protein similar to TcdE of 
C. difficile. In C. difficile, TcdE has been suggested to be important in secretion of toxins 
TcdA and TcdB (37). Of the two C. sordellii strains sequenced, one contained a full-
length gene for expression of TcsH while the other contained a truncated tcsH gene. 
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One of the unique characteristics of the C. sordellii pathogenicity locus is that tcsH and 
tcsL are expressed in opposite directions (36). 
 Another gene that has been identified on the C. sordellii pathogenicity locus is 
tcsR which is homologous to other sigma-factor genes (36). The gene is located 
upstream of tcsH and is transcribed in the same direction, opposite to tcsL. When TcsR 
was deleted, it was seen that the expression of C. sordellii cytotoxins TcsH, TcsL, and 
TcdE was decreased and the expression levels were recovered when tcsR was inserted 
back into the genome (36). This supports the understanding that TcsR is a regulatory 
sigma factor responsible for driving toxin expression. Interestingly, other clostridial 
pathogenicity loci contain an anti-sigma factor, such as tcdC in C. difficile, that is 
responsible for regulating the sigma factor (TcdR) activity and down-regulating toxin 
expression, but there is no homologous gene found on the pathogenicity locus of C. 
sordellii (36)(38). 
Cell wall 
hydrolase 
TcsL TcsE TcsH TcsR RecA 
Cell wall 
hydrolase 
TcsL TcsE 
Truncated 
TcsH 
TcsR RecA 
Figure 1-1: C. sordellii pathogenicity locus. The major genes expressed in the 
pathogenicity locus are shown, including the direction of expression for a strain 
expressing TcsH (top) and one lacking TcsH expression (bottom). The genes shown 
are cell wall hydrolase (red), tcsL (blue), tcsE (green) tcsH and truncated tcsH 
(orange), tcsR (light purple), and recA (tan). Strains VPI 9048 (top) and ATCC 9714 
(bottom) represented above. Adapted from Sirigi Reddy et al. (36). 
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 The pathogenicity locus for C. sordellii contains characteristics that suggest it is a 
mobile element within the bacterial genome. Sequencing identified several genes, such 
as transposase elements and recA, that are important for gene mobility and 
homologous recombination (36). This supports the idea that is held for C. sordellii and 
other toxin-expressing Clostridium that the toxin genes and pathogenicity loci may have 
derived from one source that was then shared between the species (39). The 
understanding of the pathogenicity locus as a mobile element of the genome also 
explains why not all C. sordellii strains and isolates contain the pathogenicity locus or 
contain both tcsH and tcsL genes (40)(28). 
 Work done using PCR amplification has identified the presence of tetracycline 
resistance genes in several C. sordellii isolates from cattle (27). The amplified genes 
were identified as tetA(P) and tetB(P) which have been shown to be located on 
transposons within the bacterial genome (27). The study showed that both genes were 
present in each of three C. sordellii isolates studied and that each isolate was resistant 
to oxytetracycline while two of the isolates were resistant to lincomycin. 
 Until recently, genetic manipulation in Clostridial species has been extremely 
difficult. The bacteria are resistant to DNA transformation so the introduction of outside 
DNA and plasmids is difficult (41). In 2007, the Nigel Minton group created a ClosTron 
gene knockout strategy that relies on E. coli conjugation to introduce a plasmid that can 
recombine with the bacterial genome to introduce a targeted knockout (42). So far, this 
technique has only been used twice in C. sordellii, to introduce a deletion of tcsL and 
tcsR (5, 36). Because of the limited number of studies in C. sordellii, a lot of questions 
still remain regarding the importance and impact of specific genes. 
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Role of toxins in disease and animal models 
 C. sordellii is known to produce a number of toxins that are implicated in driving 
the disease seen during infection. Published in 1962, MacLennan describes that C. 
sordellii produces a lecithinase (later known as phospholipase C), a hemolysin, a 
fibrinolysin, a urease, and lethal toxin (TcsL) (3). Evidence for expression of a 
hemorrhagic toxin, called TcsH, was identified in 1969 as well as a deoxyribonuclease a 
few years later (4). 
 Lecithinase, or phospholipase, production has been observed in C. sordellii as 
well as other Clostridium species: C. perfringens, C. bifermentans, and C. novyi (3, 43, 
44). Although the lecithinase activity of C. sordellii was identified by the 1940s, the 
characterization was limited to comparisons to other clostridial lecithinases and the 
antigenic similarity to those same lecithinases (43, 44). A more detailed study published 
in 2003 cloned the C. sordellii phospholipase and tested its ability to hydrolyze egg 
phospholipids as well as test hemolysis activity. The authors found that C. sordellii 
phospholipase was active in both enzymatic assays, although at decreased rates 
(38.2% and 7.6%, respectively) when compared to the phospholipase of C. perfringens, 
with which it shares 53.4% amino acid identity (45). 
 C. sordellii has been shown to express a gene (nanS) that encodes for a 
neuraminidase protein (46). The neuraminidase is a cysteine dependent enzyme that is 
responsible for removing sialic acid moieties and is believed to be important in infection. 
Previous work has shown that the neuraminidase can increase the proliferation ability of 
a promyelocytic cell line. The increase in cell proliferation is believed to be important for 
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the leukemoid reaction, or increase in white blood cells in the bloodstream, that occurs 
during infection and correlates with mortality outcomes (46). 
 Another toxin that is produced by C. sordellii is a cholesterol-dependent cytolysin 
called sordellilysin (40). The sordellilysin gene was identified in C. sordellii isolates 
using the sequence for Clostridium perfringens perfringolysin O and expression was 
detected using antibodies to perfringolysin O (40). Experiments performed with different 
cell lines showed that sordellilysin is capable of inducing cytotoxicity in cells and that the 
concentration of sordellilysin required was ten-fold higher than when compared to the 
concentration needed for TcsL-induced cytotoxicity in mice (40). 
 The two main toxins of C. sordellii are the hemorrhagic toxin (TcsH) and lethal 
toxin (TcsL). Crude filtrates and culture broth were seen to induce edema and lesions 
that led to death when injected into guinea pigs (47). TcsL was shown to be an exotoxin 
based on the observation that rabbit antiserum provided protection when injected into 
mice alongside TcsL (1). It was not until several decades later that Arseculeratne, 
Panabokke, and Wijesundera presented data suggesting a second major toxin was 
produced by C. sordellii that was responsible for hemorrhaging when injected into 
guinea pig skin (4). The hemorrhaging caused by what would later be known as TcsH 
was also seen when crudely purified toxin was injected into the skin and tissue of 
rabbits, mice, and rats (4). 
 TcsH purification and characterization was first reported by Ramon Martinez and 
Tracy Wilkins in 1988. They found TcsH to be 300 kDa in size with a pI of 6.1 based on 
isoelectric focusing (7). When the toxin was injected into rabbit ileal loops, fluid 
accumulation and hemorrhaging occurred (7) and similar hemorrhaging and destruction 
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of the mucosal layer was seen when TcsH was injected into a guinea pig ileal loop (6). 
After initial characterization, further work on TcsH focused primarily on the cytotoxic 
effects in cell culture. 
 The purification and characterization of TcsL was published in 1987 by Michel 
Popoff. The original work suggested TcsL was a 250 kDa protein (6); we know now it is 
270 kDa. TcsL was shown to be lethal when injected into mice and caused edema and 
erythema when injected into guinea pig skin. TcsL also induced fluid accumulation in an 
ileal loop of guinea pigs, but this was not accompanied with any histological changes 
(6). In 2007, it was shown that when TcsL was injected intraperitoneally into mice, TcsL 
killed the mice by causing vascular permeability in the lungs and massive fluid secretion 
(48). The mice initially displayed a loss of mobility and ataxia, darkened tails, and signs 
of dehydration 6 hours after toxin injection. The fluid build-up in the thoracic cavity 
occurred within hours of TcsL injection, and edema was seen around blood vessels in 
the lung. The hearts of intoxicated mice were also shown to exhibit edema (48), which 
suggests TcsL acts upon endothelial cells to disrupt tight junctions and make the 
vasculature leaky, something that has been reported in cell culture (49). 
 TcsL is thought to be the main virulence factor in C. sordellii based on several 
studies. A study was performed using a clinical isolate of C. sordellii lacking TcsL 
expression compared to a TcsL-positive strain (50). The authors saw that infection of 
mice and rats with the TcsL-negative strain did not lead to death, and the infected 
rodents also lacked symptoms often associated with C. sordellii infection, such as 
decreased mobilization and signs of dehydration. It was also seen that intoxication with 
cultures from the TcsL-negative strain did not lead to death in the animals but all the 
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animals intoxicated from the TcsL-positive strain died (50). Work published a year later 
also showed that TcsL is required for virulence in C. sordellii infections. Glen Carter and 
colleagues were able to introduce a mutation into tcsL of the C. sordellii genome which 
prevented expression of TcsL (5). The mice infected with the TcsL-deficient strain all 
survived while none of the mice infected with the wild-type strain did, and the TcsL-
deficient strain did not induce symptoms of illness. Further infection of the uterus of 
mice with the two C. sordellii strains showed that the TcsL-positive strain induced 
edema of the uterine tissue, which was absent in mice infected with the mutant strain 
(5). This shows the importance of TcsL as the primary virulence factor for C. sordellii. 
 
TcsH and TcsL 
 
Large clostridial toxins 
 The large clostridial toxins (LCTs) are a group of toxin proteins expressed by 
species in the bacterial Clostridium family. The family consists of the lethal toxin (TcsL) 
and hemorrhagic toxin (TcsH) from C. sordellii, TcdA and TcdB of C. difficile, α-toxin of 
C. novyi (Tcnα), and C. perfringens large cytotoxin (TpeL). The toxins are large proteins 
ranging from 250 to 307 kDa in molecular weight and are expressed as a single protein. 
Each toxin is an AB toxin that consists of an enzymatic A portion and a B portion 
responsible for host cell binding and translocation. The toxin activity relies upon the 
enzymatic domain to transfer a glucose moiety from host cytosolic UDP-glucose, or N-
acetylglucosamine for Tcnα, onto small GTPases in the host cell. Each toxin consists of 
four distinct subdomains: a CROPs (combined repetitive oligopeptides) domain, pore 
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formation/translocation domain, autoprocessing domain, and enzymatic or 
glucosyltransferase domain (GTD) (Figure 1-2).  
 The LCTs are homologous and share a high level of sequence identity. The 
highest identity is shared between TcdA and TcsH and between TcdB and TcsL (Table 
1-1). The high homology across species supports the idea that the toxins may have 
originated from a common ancestor and that a possible duplication event gave rise to 
TcdA and TcdB of C. difficile and TcsH and TcsL of C. sordellii. Much of the research 
performed on LCTs has been done on TcdA and TcdB, but because of the high 
sequence and structural homology, the model of intoxication and mechanisms of toxin 
action are thought to be extremely similar. 
 
 
 
 
Figure 1-2: Domain structure of TcsH and TcsL. TcsH and TcsL contain four 
distinct domains: glucosyltransferase domain (red), autoprocessing (blue), delivery 
or translocation domain (yellow), and a CROPs domain (green). The toxins are AB 
toxins consisting of an A enzymatic portion and a B region that is responsible for 
delivery of the toxin’s enzymatic portion. 
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Holotoxin TcdA TcdB TcsH TcsL Tcnα 
TcdA           
TcdB 48%         
TcsH 78% 48%       
TcsL 48% 76% 49%     
Tcnα 31% 30% 31% 30%   
 The large clostridial toxins of C. sordellii and C. difficile are not only structurally 
homologous but the sequence conservation resulted in similar epitopes that provide 
cross-reactivity between antibodies. When TcsL was first purified and characterized, it 
was shown that the antibody that neutralized TcsL was also able to recognize and bind 
TcdB (6). Purification of TcsH and studies using antiserum for TcsH also showed 
specificity for TcdA as well (7). The similarity seen between TcsH/TcdA and TcsL/TcdB 
was recognized before the toxins were fully characterized (51), and it was even thought 
that pseudomembranous colitis, caused by C. difficile infection, may have been caused 
by C. sordellii because antiserum toward TcsH and TcsL protected against colitis (52, 
53). Even after C. difficile toxins were implicated as responsible for causing 
pseudomembranous colitis, antitoxin toward TcsH and TcsL was studied for its 
Table 1-1: Protein sequence identity between large clostridial toxins. Protein 
sequences for TcdA and TcdB from C. difficile strain 10643, TcsH and TcsL from C. 
sordellii strain JGS6382, and Tcnα from C. novyi ATCC 19402 (168) were compared 
by Protein BLAST. The values shown indicate the amino acid sequence identity 
between each of the large clostridial toxins. 
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protective effects (54), supporting the significance of the sequence similarity shared 
between TcsH/TcdA and TcsL/TcdB. 
 
Host cell binding 
 The C-terminus domain of both TcsH and TcsL contains amino acid repeats that 
have been described as the host cell binding domain in TcdA. The TcdA C-terminal 
sequence was shown to have a series of combined repetitive oligopeptides, or CROPs. 
TcdA contains seven long repeats of 90 amino acids and thirty-one shorter repeats of 
60 and 63 amino acids (55). The short repetitive amino acid sequences were grouped 
Figure 1-3: Model of TcsH and TcsL Intoxication. (1) TcsH and TcsL enter cells 
by first binding to a cell receptor at the plasma membrane and (2) being taken up 
into the cell through clathrin-mediated endocytosis. (3) The toxin is then trafficked to 
the endosome which undergoes a drop in pH during maturation. (4) The pH drop 
facilitates conformational change of the translocation domain (yellow) and allows for 
the formation of a pore through which the autoprocessing domain (blue) and GTD 
(red) are shuttled to the host cytosol (5). In the cytosol, the autoprocessing domain 
encounters host IP6 and cleaves the GTD (6) and the free GTD travels to and 
glucosylates host GTPases (7). 
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into five CROPs regions that are separated by long repeats (56). A crystal structure was 
obtained of a portion of the TcdA CROPs in 2005 and used to create a model for the 
entire domain of TcdA as well as a model of the shorter TcdB CROPs as well (57). The 
proposed structures for the TcdA and TcdB CROPs were supported by electron 
microscopy imaging that showed the extended CROPs in the context of the holotoxin 
(Figure 1-4) (58). The modular nature of the repetitive repeats in the binding domains, 
which has also been seen in the sequences of TcsH and TcsL, suggests a similar 
structure for the CROPs that can be easily modeled by adding on or subtracting the 
correct number of repeats from the structure. 
 Work implicating the CROPs in host cell binding was performed for TcdA. It was 
shown that the TcdA CROPs is able to recognize sugar moieties found on the surface of 
host epithelial cells in vitro (59). The importance of the C-terminal repeats of the CROPs 
for cell binding was also shown separately by Frey and Sauerborn. Frey was able to 
show that an antibody (PCG-4) which protects against TcdA enterotoxicity, binds to the 
CROPs region and inhibits cell binding (60, 61). Sauerborn and his colleagues 
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expressed short segments of the TcdA repeats and showed that treatment of cells with 
the repeats protected the cells from intoxication by TcdA (62). The work also shows that 
protection of cells was achieved by the use of antibodies specific to the CROPs region. 
Support for the importance of TcdA binding to sugars was shown when cells were 
treated with purified lectins, which decreased the cytotoxicity of TcdA. 
Figure 1-4: Structure of CROPs domain. Models based on the crystal structure of 
a single CROP repeat were created for TcdA (A) and TcdB (B) showing the structure 
of the entire domain by combining repeats of the solved structure. EM structures for 
TcdA (C) and TcdB (D) holotoxins confirm that the modeling is consistent with the 
CROPs regions seen in each toxin. Adapted from Ho et al. and Pruitt et al. (57, 58). 
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The binding of TcdA to carbohydrate was shown in a co-crystal structure of a 
TcdA CROPs segment with a-Gal-(1,3)-b-Gal-(1,4)-b-GlcNAcO(CH2)8CO2CH3 (63). 
The crystal structure suggests that TcdA (and perhaps other LCTs) bind glycolipids 
and/or glycoproteins and that multiple binding sites increase the avidity of the toxin 
binding to the host cell, even if the affinity for individual carbohydrates is low. The ability 
of TcdB to bind carbohydrates was shown to be similar to TcdA, and both displayed 
tolerance for variation in the glycolipid receptors (64). 
The role of the CROPs in TcdB binding is less clear. Bezlotoxumab is an 
antibody that had been developed by Merck for the treatment of C. difficile infections 
and has shown protection against recurrence of C. difficile infection in clinical trials (65). 
The antibody binds specifically to the CROPs region on TcdB and the complex has 
been crystallized. This antibody interaction protected cells from TcdB cytotoxicity (65). 
This work suggested that the CROPs of TcdB was also important for cell binding. 
 Interestingly, recent work has shown that the CROPs of large clostridial toxins 
may not be the only binding site for toxin receptors. Olling and colleagues used a 
truncated TcdA lacking the CROPs to show that binding and intoxication of cells was 
still possible (66). When truncated, CROPs-less TcdA was added to 3T3 and HT29 
cells, the toxin still showed cytopathic effects, although at a 5 to 10-fold lower potency 
than full-length TcdA, but was just as potent as full-length TcdA on CHO cells. The 
cytopathicity of truncated TcdA was not inhibited by either full-length TcdA or CROPs 
domain peptides, suggesting that a separate binding event was responsible for the 
cytopathicity of truncated TcdA. Recent work from our lab identified PVRL3 as a 
receptor for TcdB. A truncated version of TcdB that does not contain the CROPs also 
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binds the receptor (67). Another report found that TcdB was able to bind to chondroitin 
sulfate proteoglycan 4 and be internalized in cells, and that the binding did not occur 
with the CROPs of TcdB alone (68). These works suggest a model of binding for large 
clostridial toxins where two binding events occur, one mediated by the CROPs that 
relies on binding to carbohydrates and a second binding event that relies on a receptor 
binding to the toxin outside of the CROPs. 
 After binding, the toxins are internalized into cells. The internalization of TcdA 
and TcdB has been reported to occur by clathrin-mediated endocytosis (69). TcdB-
induced cell rounding was inhibited by dynasore, an inhibitor of dynamin which is 
important for pinching off endocytic vesicles, and by chlorpromazine, a chemical that 
prevents clathrin-coated pits from forming. Clathrin-mediated endocytosis of TcdB was 
also implicated by the siRNA depletion of clathrin heavy chain and the use of a 
dominant-negative dynamin. The same inhibition of cell rounding was seen for TcsL, 
TcdA, and Tcnα when cells were treated with dynasore and chlorpromazine (69). The 
work shows that TcdB internalization occurs by clathrin-mediated endocytosis and 
suggests the same mechanism of internalization is conserved for all the large clostridial 
toxins. 
 
Pore formation 
 Work was done to understand the mechanisms of cell entry for the LCTs. The 
authors showed that TcdB enters cells through endocytosis based on the inability of 
antitoxin to prevent cytopathicity after intoxication and due to a decrease in toxicity 
when cell lines that are deficient in endosomal acidification were intoxicated (70). 
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Qa’Dan then showed that the cytopathic effects of TcsL were blocked when cells were 
treated with endosomal and lysosomal acidification inhibitors such as bafilomycin and 
ammonium chloride (71). The work also showed that the cytopathic effects on cells 
occurred faster when the toxins were exposed to a low pH environment, under pH 5.5, 
than compared to toxins held at a neutral pH. They were also able to show that 
exposure of TcsL to acidic pH causes a conformational change in the toxin that allows 
for an increased exposure of hydrophobic regions, based on an increase in TNS 
fluorescence (71). Studies done previously by the same group showed the reliance on 
pH for cytopathic effects and conformational change to also be true for TcdB (72). This 
supported that delivery of the enzymatic GTD required a conformational change in the 
toxin that allowed delivery into the host cell, which occurs commonly in AB toxins to 
deliver the enzymatic A portion. Work was able to show this conformational change in 
the translocation domain by EM by exposing TcdA to neutral and acidic pH and 
comparing the structure (58). 
 Based on the knowledge that a conformational change, most likely occurring 
during endosomal maturation, was responsible for toxin entry and intoxication, Barth et 
al. looked at whether TcdB was capable of forming pores in the membrane. They 
measured the ability of TcdB to form pores in cells loaded with radioactive 86rubidium 
(86Rb) (73). By adding TcdB and decreasing the extracellular pH, the cells (both Vero 
and CHO) released 86Rb indicating the formation of a pore. Further, they showed that 
the pore formation was blocked by an antibody that prevented cell binding but not 
blocked by an antibody for the GTD, thus localizing the pore formation ability to the non-
enzymatic portion of the toxin. The localization of the pore forming activity was 
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supported by the use of a TcdB construct lacking the GTD that was still able to cause 
86Rb release. The authors also performed the 86Rb release assay with TcsL and 
showed that TcsL induces pore formation after the toxin environment is acidified (73). 
The ability of TcdA, which is highly homologous to TcsH, to form pores was shown as 
well by the release of 86Rb in HT-29 cells (74), supporting the conserved nature of pore 
formation for large clostridial toxins. 
 Further work published in 2003 was done focusing on the localization of the 
autoprocessing domain of TcdB during intoxication. The authors showed that the 
cleaved GTD was found in the cytosol after endocytosis by cell fractionation and they 
showed that the C-terminal portion of TcdB containing the binding and pore formation 
domains remained bound to the membrane (75). Although previous work suggested that 
the membrane bound portions of TcdB were located in endosomal membrane, Pfeifer 
showed that the TcdB C-terminus was in the endosome based on immunofluorescent 
co-localization with Rab5, an endosomal marker, while the TcdB GTD fluorescent signal 
became diffuse in the cytosol following intoxication. 
 
Autoprocessing 
 The cleavage site for the large clostridial toxins was not known until 2005. It was 
found to be located between the leucine 544 and glycine 545 in TcdB based on 
holotoxin cleavage in the context of cells (76). The location of cleavage corresponds to 
leucine 543 in TcsL and leucine 542 in TcsH from C. sordellii strain JGS6382. It was 
originally believed that the cleavage was performed by a host cell protease yet the 
autoprocessing was not inhibited even in the presence of a variety of cell protease 
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inhibitors (76). Work done by Reineke et al. to identify the host factor involved in 
cleavage of the holotoxin was surprising in that it was not a host protease but a small 
molecule, inositolphosphate, that was identified as required for toxin cleavage (77). 
They identified inositolhexakisphosphate (IP6) as the compound that, when combined 
with TcdB, had the highest cleavage activity. It was shown that IP6 was also necessary 
for cleavage of TcsL, as well as other LCTs TcdA and Tcnα. 
 Further work was able to identify the mechanism of action for autoprocessing in 
the large clostridial toxins. Using TcdB, Egerer et al. showed autocatalysis was inhibited 
by the addition of N-ethylmaleimide, an inhibitor of cysteine-dependent reactions (78). 
They were also able to identify a cysteine, C698, which is conserved among the large 
clostridial toxins and homologous to a cysteine present in another cysteine proteases, 
RTX toxin of Vibrio cholera (79). When the cysteine was mutated to an alanine, the 
autoprocessing ability of TcdB was inhibited (78). 
 In 2009, Rory Pruitt from our lab determined the crystal structure of the TcdA 
autoprocessing domain (80). In this paper, he defined the autoprocessing domain as 
amino acids 543-809 for TcdA. This corresponds to amino acids 544-807 in TcsL based 
on sequence homology. Using his crystal structure, Pruitt determined that IP6 bound 
one face of the toxin domain and that the IP6 binding site was separated from the 
autoprocessing active site by a β-flap structure. Pruitt also showed that when IP6 bound 
to the autoprocessing domain, it induced a conformational change, and proposed that 
the added stability of IP6 binding allows for the autoprocessing domain to be in the 
active conformation (80). 
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 The first study of the TcsL autoprocessing domain was published in 2011 by 
Guttenberg and colleagues. In this paper, they expressed a fragment of TcsL that 
contained the glucosyltransferase domain and the autoprocessing domain, amino acids 
1-807 (81). As was seen previously with TcdA and TcdB, TcsL autoprocessing was 
induced with addition of IP6 to the TcsL toxin fragment and the glucosyltransferase 
domain was released. This study showed that the autoprocessing of TcsL did not 
require any other toxin domains beyond the first 807 amino acids. Interestingly, when 
the cleavage of the GTD was performed with the TcsL holotoxin at pH 7.4, the 
autoprocessing efficiency was greatly diminished and the toxin was much more stable, 
even when compared to TcdB or Tcnα. When TcsL was shifted to a lower pH, more IP6 
was able to bind and the autoprocessing activity increased (81). 
Guttenberg also showed that when the catalytic cysteine (C698) was mutated to 
an alanine, cleavage of the toxin fragment and release of the GTD no longer occurred, 
even in the presence of 100-1000 fold more IP6 than needed for the original TcsL 
fragment (81). When Vero cells were treated with TcsL C698A, the cells did not show 
cytopathic effects after six hours compared to cells treated with wild-type TcsL. This 
supported the identification of the conserved cysteine, which had previously been 
identified for TcdA and TcdB, as important for toxin autoprocessing in the large 
clostridial toxins and suggested that autoprocessing and release of the GTD is 
important for toxin activity. Interestingly, recent work has shown that the loss of 
autoprocessing activity in TcdB does inhibit cytotoxicity (82).  
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Glucosyltransferase 
 Studies to determine the localization of the enzymatic domain, which would 
become known as the glucosyltransferase domain (GTD), began to be published in 
1997. It was known by then that the C-terminus of the toxin was involved in cell binding 
and that the middle portion of the toxin played a role in translocation, so it was believed 
that the N-terminus of the LCTs would be important for the enzymatic activity. Fred 
Hofmann first published data supporting this when he expressed truncation mutants of 
TcdB focusing on the N-terminus. He found that the fragment expressing amino acids 1-
546 of TcdB was the shortest fragment that kept full glucosylation activity against 
targeted GTPases (83). He was able to confirm this when TcdB 1-546 was 
microinjected into NIH 3T3 cells and the toxin fragment induced cytopathic effects 
similar to full length TcdB. 
The TcsL glucosyltransferase domain was defined as amino acids 1-546 through 
the creation of a truncated TcsL fragment that was capable of full glucosylation (84). 
This work showed that for TcsL, truncation to a fragment containing amino acids 1-546 
did not lose glucosylation activity, but a fragment of amino acids 1-517 did show 
decreased glucosylation activity. The definition of the GTD and its role in GTPase 
specificity was supported when chimeras were made, exchanging fragments of TcdB 
and TcsL. Based on the glucosylation profiles (as described further below), Hofmann 
was able to show that amino acids 364-516 largely play a role in determining whether 
the GTD has a TcdB-like or TcsL-like glucosylation profile (84). 
 It has been observed that treatment of cells with TcsL causes cell rounding and 
disruption of the actin fibers of the cytoskeleton. The use of UDP-[14C]-glucose showed 
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that TcsL was able to glucosylate small 21 kDa proteins in HeLa cells and when 
individual GTPases were used, TcsL was able to glucosylate HRas, Rap2, and Rac1 
but not Cdc42 or RhoA (85). TcsL was shown to glucosylate Rac1 and HRas in NIH 3T3 
cells (86). The glucosylation required UDP-glucose, which was shown when cells 
lacking UDP-glucose did not show cytopathicity after TcsL treatment until UDP-glucose 
was microinjected into cells (85). This same work was able to localize the glucosylation 
of the GTPases by TcsL to the threonine at amino acid 35 based on the presence of 
radioactively labeled UDP-glucose on protein fragments of treated HRas. The authors 
were also able to show that the glucosylation occurred after internalization of TcsL by 
microinjecting TcsL into cells and seeing cytopathicity as well as the ability to protect 
cells by injecting anti-TcsL antibodies into cells to block the toxin activity. 
 The exact GTPases targeted by TcsL seem to be dependent on the strains of C. 
sordellii from which the toxin is isolated. TcsL can modify Rac, Ras, and Rap (as 
described above) but can also glucosylate Cdc42 or Ral, depending on the strain of 
origin (87). The same work also showed that Ral is glucosylated at threonine 41, the 
equivalent of threonine 35 in other targeted GTPases. 
 The first study looking at the specificity of glucosylation by TcsH was published 
by Harald Genth and colleagues in 1996. They found that TcsH glucosylated RhoA, 
Rac1, and Cdc42 but not HRas, Rap1, Ral or several other GTPases (88). The TcsH 
glucosylation of RhoA was shown to occur at threonine 37, equivalent to threonine 35 of 
other GTPases as previously reported for TcsL, and that the glucosylation also occurred 
in vivo in NIH 3T3 cells. In depth studies of the glucosylation profiles of the large 
clostridial toxins, including TcsH and TcsL, have been done using both a proteomics 
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approach of detecting glucosylation in cells (89) as well as in vitro glucosylation 
reactions using recombinant GTPases and GTDs from a variety of LCTs (90). A 
summary of glucosylation profiles is shown in Table 1-2.  It is of note that the 
glucosylation profile of TcsH is like that of TcdA and TcdB of C. difficile and differs from 
the glucosylation profile of TcsL. 
 
 It has been shown that for the glucosyltransferase domain to perform its 
enzymatic function, it requires a divalent cation. Based on work showing that other 
glucosyltransferases are stimulated by a manganese ion, Just and his colleagues tested 
whether this was true for TcsL GTD. They found that TcsL glucosylation was stimulated 
with manganese ions (Mn2+) as well and that glucosylation was blocked by the addition 
of EDTA, a chelator of Mn2+, to the reaction (86). The importance of Mn2+ for TcsH 
glucosylation activity was also shown by the addition of divalent ions to chelated toxin, 
Rho (A/B/C) RhoG Rac1 Cdc42 H/K/N Ras RRas Ral (A/B/C) Rap1 Rap2
TcsH-9048 + + + + * * * *
TcsL-9048 * * + * + * + + +
TcsL-82 * * + + + + + +
TcsL-6018 + + + + + + + +
TcdA-10463 + + + + * * *
TcdA-C34 + + + + + +
TcdB-10463 + + + +
TcdB-C34 + + + + + + +
TcdB-CD196 + + + +
TcdB-1470 * + + * + + + +
Tcnα + * + +
TpeL + + * * +
Table 1-2: Glucosylation profiles for the large clostridial toxins. Toxins from 
different strains were analyzed for their ability to modify Rho and Ras family 
GTPases and the profiles were summarized. + indicates a target for glucosylation 
and * indicates glucosylation has been seen at low levels in some in vitro studies. 
Adapted from Zeiser et al. and Genth et al. (89, 90). 
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of which only Mn2+ and to a lesser extent cobalt (Co2+) were able to stimulate TcsH 
glucosylation (88). 
 To better understand the mechanism of glucosylation by large clostridial toxins, 
work was done to identify key amino acids in the toxin enzymatic activity. A conserved 
motif of two aspartates (DxD) was found in a yeast mannosyltransferase enzyme that 
was shown to be conserved across a number of glucosyltransferases (91). Based on 
this motif, Busch saw the presence of the DxD motif in the glucosyltransferase domain 
of TcsL, as well as the other large clostridial toxins (92). Busch and colleagues mutated 
each aspartate to alanine and saw that the ability to glucosylate GTPases was greatly 
inhibited; the introduction of a double mutant inhibited glucosylation below levels of 
detection. Other amino acid residues around the DxD motif were modified in the TcsL 
GTD but the mutants were not inhibited in glucosylation activity (92). 
 Structural work has also been done to understand the mechanism of 
glucosylation and how it affects the host GTPases targeted. GTPases cycle between a 
GDP-bound state and a GTP-bound active state and the cycling is mediated by guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). In the 
GTP-bound state, the swtich I region of Ras is found in two different conformations, one 
which facilitates the interaction with Ras GAPs (93). When the GTPases are 
glucosylated by LCTs, the ability of the GTPase to switch into the active conformation is 
blocked, as shown for HRas upon TcsL glucosylation (94). Interestingly, glucosylation 
does not occur on the loop of the GTPase that changes conformation but stabilizes the 
GTPase in the inactive conformation (95). It has been shown that by preventing 
GTPases to switch to the active conformation upon glucosylation, the GTPases have a 
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decreased affinity toward their effectors, below physiologically relevant levels, and are 
rendered inactive (94–96).  
 
Host GTPases 
 
 GTPases are small proteins found in cells that act as molecular switches and are 
involved in many different cellular processes and signaling pathways.  There are 
hundreds of GTPases expressed in mammalian cells, with over 60 in the Ras 
superfamily alone (97, 98). Within the Ras superfamily are five groups of GTPases: 
Ras, Rho, Rab, Arf, and Ran GTPases. TcsH and TcsL are known to glucosylate 
Figure 1-5: Structure of GTPase switch region conformations. The crystal 
structure of the two conformations for the switch 1 region in Ras GTPases is shown. 
The switch one region shown in purple shows the position of the tyrosine (A, red 
box) in the context of the Ras structure. (B) The active conformation of Ras (and 
Rap1) on the left shows the tyrosine pointing away from Ras and allowing for other 
molecules to bind and interact with Ras, while the tyrosine is pointed inward in the 
second conformation and prevents binding of effectors. Adapted from Hall et al. and 
Geyer et al. (93, 169). 
B 
 33 
GTPases from the Rho and Ras subfamilies, so these groups will be the focus moving 
forward. The GTPases are responsible for a wide variety of cell functions including cell 
morphology and motility (99–101), cell polarity (102–104), and cell cycle progression 
(105, 106). 
 GTPases are constantly cycling between the active and inactive state. In the 
active state, the protein is bound to GTP and then switches to binding GDP in the 
inactive state. When in the active state, GTPases hydrolyze GTP into GDP and interact 
with other host protein effectors to perform a variety of functions and signaling events. 
The cycling between active and inactive states is mediated by GAPs and GEFs, which 
are also important for regulating the activity of GTPases. GAPs, GTPase-activating 
proteins, stimulate the hydrolysis of GTP to switch GTPases to the inactive state, while 
guanine nucleotide exchange factors (GEFs) facilitate the release of GDP and binding 
of GTP to return the GTPase to an active state. This is depicted in Figure 1-6. 
Figure 1-6: GTPase activation and inactivation. Regulation of Rho and Rac 
GTPases is achieved by GEFs and GAPs. GAPs inactivate GTPases by hydrolyzing 
GTP to leave the GDP-bound GTPase. GEFs activate GTPases by facilitating 
exchange of GTP- instead of GDP-bound states. Once GTPases are in the active 
state, they can interact with their effectors to perform functions within the cell. 
Adapted from Jank et al. 2007 (170). 
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 The GAPs and GEFs that regulate GTPases are abundant in cells, over 60 GAPs 
and 70 GEFs have been identified that are specific to Rho GTPases alone (98). The 
multitude of regulators means that there is a redundancy for each GTPase and shows 
how complex and varied the roles of the GTPases are. There are also large numbers of 
effector proteins that the GTPases interact with that are only present in limited locations 
or times within the cell. This increases the specificity and the diversity of the functions 
each GTPase can perform through spatial and temporal regulation (97, 107). It has 
even been shown that Rho GTPases can be activated by Ras or Rho GTPases to 
increase the complexity of the signaling events that occur (99, 108, 109). 
 
Role of Rac in cells 
 Rac GTPases are important for a number of cellular functions but one of the 
primary roles of Rac is the regulation of the host cytoskeleton. Rac is important in 
controlling the cytoskeleton, particularly the assembly and disassembly of actin 
filaments. The formation of lamellipodia and membrane ruffles are driven by Rac and 
are important for the motility of cells (99, 100, 108). Rac regulation of the cytoskeleton is 
also important in neuronal cells where it promotes axon growth, membrane protrusions, 
and an increase in the number of dendritic spines (110–112). The role of Rac in 
cytoskeleton regulation is very important to cells because of the many functions that rely 
on or interact with the cytoskeleton. 
 Other important cellular functions regulated by Rac GTPases include cell cycle 
progression, kinase signaling pathways, and cellular morphology. Rac regulation of cell 
cycle progression occurs in part through control of the cytoskeletal events important for 
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growth and duplication but also controls the expression of cyclins, such as D2 in B cells 
and D1 during the G1 phase (113, 114). There are many kinase signaling pathways and 
Rac is also important for activating some of these in cells as well, such as the JNK and 
p38 MAP kinase pathways (115, 116). Cell morphology, particularly in tissues, is 
dependent upon the establishment of cell adherens junctions and tight junctions that 
create a barrier between the apical and basolateral sides of polarized cells. Rac enables 
the production of these junctional interactions between cells through cadherin-
dependent and integrin-based cellular contacts (117–119). 
 
Role of Ras in cells 
 The major role of Ras GTPases in cells is the control of cell cycle progression 
and proliferation. The majority of research that has been done on Ras GTPases and 
signaling relate to cancer biology due to the fact that many of the regulators have been 
indicated as or suspected to be oncogenes and anti-oncogenes (120, 121). Many of the 
Ras family proteins, as well as their regulators and effectors, are transformed in some 
way in cancer cells and immortalized cell lines used in research, with Ras mutations 
detected in 30% of cancer cells (120). Ras activation is important for the downstream 
signaling of the PI3K/Akt, Raf/MEK, and Ral pathways that regulate cell survival and 
proliferation through the activation and inhibition of transcription factors (122). Ras 
GTPases are also vital for the regulation of cell cycle progression through kinase 
signaling pathways as well as the control of transcription factors. The disruption of these 
pathways by glucosylation by LCTs, particularly TcsL, leads to cell cycle inhibition and 
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eventual cell death when pro-apoptotic pathways are activated and cell survival 
pathways are inhibited (123, 124). 
 
Localization of Rac and Ras GTPases 
 Rho family GTPases have been reported throughout the cell, and Rac 
localization can be diverse as well. Rac is typically found associated with cellular 
membranes and is most often associated with the plasma membrane at the cell surface 
where it plays an important role in cytoskeleton regulation (125, 126). Rac1 has been 
localized in both cytosolic and membrane fractions by cellular fractionation and has 
been visualized to be found primarily on plasma membranes (125, 127, 128). Work 
focused on the Rac2 isoform has shown that it is located in the cytoplasm but also on 
endosomal membranes, and that localization to membranes increases particularly upon 
assembly of the NADPH oxidase complex in neutrophils (125, 129). Work has shown 
that despite the varied localization of Rac GTPases, the protein must be trafficked 
through the endosome to be activated. The authors show that activation of Rac is 
inhibited by preventing endocytosis and formation of early endosomes and that 
recruitment to the endosome is regulated by Rab5 (126). This shows another layer of 
complexity in the regulation of Rac GTPases using localization and trafficking to specific 
cellular locations. 
 Ras GTPase isoforms, consisting of H, K, and NRas, are localized to the plasma 
membrane after expression and have been shown to require plasma membrane 
localization to activate signaling (130). The localization of Ras is achieved through a C-
terminal CAAX motif that is further processed to drive the protein to the membrane. 
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After expression, the CAAX motif is initially prenylated by either farnesyl protein 
transferase or geranylgeranyltranserferase to drive localization to the endoplasmic 
reticulum (ER) (131, 132). Once the Ras GTPase reaches the membrane of the ER, the 
protein is further modified by the cleavage of the AAX from the CAAX motif and either 
palmitoylated in the case of HRas and NRas or methylated as is seen for KRas (133–
136). KRas travels directly to the plasma membrane while HRas and Kras travel to the 
plasma membrane via the Golgi apparatus (131, 133). While there have been reports of 
Ras located in the nucleus, other data has suggested this may not be true (137, 138). 
Localization of Ras GTPases is limited to plasma membranes in cells and activation and 
signaling occurs at the inner plasma membrane. 
 
Research Objectives 
 
 Much of our understanding about the mechanism of action for the LCTs has 
come from work done on TcdA and TcdB of C. difficile. Our understanding of C. sordellii 
toxins TcsH and TcsL is based in part on the activity of TcdA and TcdB due to the high 
levels of homology between the toxins. This project was designed to directly test 
mechanisms of action in the context of TcsH and TcsL. There are already differences 
that are known about the toxins of C. sordellii from other large clostridial toxins. One 
main difference is the ability of TcsL to modify Ras proteins, which has been shown to 
lead to apoptosis of intoxicated cells (123, 124, 139). The other large clostridial toxins 
are unable to glucosylate Ras proteins, with the exception of variant TcdB strains. 
Differences between TcsH and TcsL and other large clostridial toxins, such as the 
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GTPases that are glucosylated, demonstrate that our understanding of one toxin is not 
always true for the other large clostridial toxins. Previous work looking at TcdA and 
TcdB has shown important differences such as differences in receptor specificity (67, 
68, 89, 140) and recent work from our lab has shown that TcdB is able to induce 
necrosis independent of enzymatic activity, which TcdA does not (82, 141). 
 While work had been done on TcsL, very little had been done looking in depth at 
TcsH. Part of this was due to the fact that TcsH is not expressed in all pathogenic 
strains of C. sordellii as well as the lack of a gene sequence until 2013 (28), which 
made studying the impact of TcsH difficult. TcsL, as well as TcdA and TcdB, had been 
expressed recombinantly in prior studies using a Bacillus megaterium expression 
system (142) but TcsH has not been reported to be expressed recombinantly. Our lab 
was able to introduce tcsH into the B. megaterium expression vector to be used for 
study alongside recombinantly expressed TcsL. 
 In order to have a better understanding of TcsH and TcsL, I began a study 
comparing the toxins of C. sordellii to their homologs of C. difficile, TcdA and TcdB. I 
wanted to understand whether the differences seen in toxicity and mechanism between 
TcdA and TcdB would be similar to differences between TcsH and TcsL. In Chapter II, I 
describe the work that was done using recombinant expressions of TcsH and TcsL and 
assays that were performed in order to delve deeper into the differences and similarities 
between the two toxins, as well as to compare them to their C. difficile homologs, TcdA 
and TcdB. We know that different cell lines have different sensitivities to the large 
clostridial toxins, so I started by looking for a cell line that was sensitive to both TcsH 
and TcsL to use for comparative studies. In addition, I worked to determine the 
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cytotoxicity of each toxin relative to each other as well as to determine the mechanism 
of cell death that each toxin induces. I report data suggesting that despite high 
homology between TcsH and TcdA and between TcsL and TcdB, it appears that the 
mechanisms of cytotoxicity and cellular responses may be similar for TcsL/TcdA and 
TcsH/TcdB instead. 
 To further build on our limited knowledge of TcsL, I undertook work to study the 
importance and role each domain had in cytotoxicity. In the context of holotoxin, 
mutations were introduced to inhibit the activity of key enzymatic activities of 
glucosyltransferase and autoprocessing in TcsL. It was seen, and described in Chapter 
III, that the glucosyltransferase activity was required for induction of cytotoxicity, but that 
the loss of autoprocessing impaired cytotoxicity. Interestingly, the introduction of 
mutations to disrupt TcsL autoprocessing resulted in different glucosylation activity for 
Rac and Ras GTPases, which may explain differences in cytotoxicity. 
The work was continued by looking at the role of a membrane localization 
domain (MLD) found within the GTD of TcsL and its role in intoxication. It had been 
reported previously that the MLD was a conserved structure found in many bacterial 
toxins and plays a role in toxin localization and membrane interaction (143–146). 
Mutations were made in the MLD of TcsL and the result on cytotoxicity and 
glucosylation ability were studied. I was able to show that the mutations impaired the 
membrane localization ability of TcsL and that the impairment led to a decrease in 
cytotoxicity and glucosylation in cells. 
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CHAPTER II 
 
COMPARATIVE STUDY OF TcsH AND TcsL WITH THEIR LARGE CLOSTRIDIAL 
TOXIN HOMOLOGUES FROM CLOSTRIDIUM DIFFICILE 
 
Introduction 
 
 Clostridium sordellii produces two large exotoxins, TcsH and TcsL, which are 
drivers of disease during infection. They are members of the large clostridial family and 
are highly homologous to TcdA and TcdB of C. difficile respectively (Table 1-1). While a 
lot of work has been done to study TcsL, almost nothing has been published on TcsH 
due to the fact that the TcsH wasn’t sequenced until 2013 (28). Much of the knowledge 
for TcsH, as well as TcsL to a lesser degree, has been determined by comparison with 
other large clostridial toxins, particularly TcdA and TcdB (147–150). Despite the high 
homology, there are many differences between the LCTs and their mechanisms of 
action that warrant investigation of TcsH and TcsL directly. 
 TcsH and TcsL, like other LCTs, act upon host cells to glucosylate specific 
GTPases and the glucosylation is thought to lead to cytopathic and cytotoxic effects 
downstream. There are two main cell death pathways in cells: apoptosis and necrosis. 
Apoptosis is programmed cell death that is distinguished by the cell’s ability to cleanly 
die without rupturing and risking an inflammatory response in the host (151, 152). While 
many stimuli lead to apoptosis, cells undergoing apoptosis exhibit several key 
characteristics such as the condensation of chromatin and the eventual activation of 
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caspases 3 and 7 (151). In comparison, necrosis is a much quicker and less organized 
mechanism of cell death. The cells exhibit a loss of membrane integrity, which can be 
measured by the release of cytosolic lactate dehydrogenase (LDH), and do not exhibit 
caspase activation like is seen in apoptotic cells (151). During both apoptosis and 
necrosis, cells experience a loss of ATP that can be measured as a marker for cell 
death. 
Recent work from our lab has shown that TcdB, which is highly homologous to 
TcsL, is able to induce necrotic cell death at higher concentrations while TcdA and 
lower concentrations of TcdB induce apoptotic cell death (82, 141). Based on this work, 
I wanted to investigate the mechanism of cell death induced by TcsH and TcsL and see 
how that compares to the homologous toxins from C. difficile. The high homology 
between TcsL and TcdB suggested that TcsL may also induce a necrotic cell death at 
higher concentrations while TcsH may only induce apoptosis similar to TcdA. 
 
 
Methods 
 
Toxin cloning, expression, and purification: 
TcsH was amplified from the JGS6382 strain of C. sordellii and inserted into a 
BMEG20 vector (MoBiTec) using BsrGI/KpnI restriction digest sites in the vector as 
reported previously (81). TcsL was amplified from the JGS6382 strain of C. sordellii 
using the same methods as TcsH and as reported in chapter III. Recombinant toxins 
(TcsH, TcsL, TcdA, and TcdB) were expressed in Bacillus megaterium using 35 mL of 
 42 
overnight culture seeded into 1 L of LB. Expression of toxin was induced at an OD600 of 
roughly 0.5 with 5 g D-xylose and grown for 4 hours at 37° C with shaking at 220 rpm. 
The cells were pelleted and resuspended in lysis buffer (20 mM KPi pH 7, 500 mM 
NaCl, DNase, and protease inhibitors (Sigma)). The bacteria were passed through an 
Emulsiflex for lysis and centrifugation performed at 48,000 g for 30 min. Supernatants 
were run over Ni-affinity, anion exchange with a gradient from 20 mM Tris pH 8 to 20 
mM Tris pH 8, 600 mM NaCl, and Superdex 200 size exclusion columns, and toxins 
eluted in 20 mM HEPES, pH 7, 50 mM NaCl.  
 
Cell culture: 
Conditionally immortalized murine pulmonary microvascular endothelial cells 
(mPMVECs) were obtained from the laboratory of Ambra Pozzi (Vanderbilt University).  
The cells were grown at 33° C using EGM-2 (Lonza) supplemented with 10 ng/mL IFN-γ 
in 5% CO2. For use, mPMVECs were transferred to 37° C for overnight growth in EGM-
2 media without IFN-γ. 
HeLa cells were grown at 37° C in 5% CO2 in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% penicillin streptomycin. 
 
Viability assays: 
HeLas and pMPVECs were plated at 5,000 cells/well in black wall 96-well plates. 
The cells were treated with toxin the following day and incubated at 37° C in 5% CO2 
for either 24 or 48 hours.  After incubation with toxin, viability was assessed by 
measuring the amount of ATP present by addition of CellTiterGLO (Promega), and the 
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luminescence read using a BioTek Synergy 4 plate reader. Relative viability was 
calculated by setting the mock treated sample readings as representing 100% viability. 
 
Caspase activation assay: 
 Caspase 3 and 7 activation levels were measured using the Apo-One reagent 
(Promega). The reagent was added to cells in a 96-well plate, toxin was added, and the 
plate was incubated at 37° C. 12 hours post-intoxication, fluorescence was read using a 
BioTek Synergy 4 plate reader. Relative caspase activation was calculated by setting 
the fluorescence of untreated cells to 1 and dividing toxin-treated fluorescence values 
by untreated fluorescence. 
 
Lactate dehydrogenase release: 
 Lactate dehydrogenase (LDH) release was determined using CytoTox GLO 
reagent (Promega). The reagent was added to cells in a 96-well plate and incubated for 
15 minutes prior to intoxication. 10 nM TcsH, TcsL, TcdA, and TcdB were added to the 
cells and the cells were incubated at 37° C. Luminescence was read every hour for 7 
hours on a BioTek Synergy 4 plate reader. Relative luminescence was determined by 
setting the luminescence of untreated cells to 1 and dividing toxin-treated cell 
luminescence by untreated luminescence. 
 
Intracellular calcium release: 
 mPMVECs were plated at 20,000 cells/well in clear bottom, black wall 96-well 
plates and incubated at 37° C. The following day the cells were washed with HBSS 
 44 
containing calcium and magnesium and 100 uL fresh HBSS was added to each well. 10 
uL/well of calcium signaling reagent, FLUOFORTE (Enzo Life Sciences), diluted 20-fold 
was added. The cells were then intoxicated with recombinant TcsH, TcsL, TcdA, and 
TcdB over a range of concentrations. The fluorescent signal was read kinetically 
overnight every 30 minutes using a BioTek Synergy 4 plate reader with the sensitivity 
setting at 40. Relative fluorescence was determined by setting the mock treated 
background fluorescence for each time point as 1 and dividing toxin-treated cell 
fluorescence by the mock-treated fluorescence. 
 
Reactive oxygen species production: 
 Reactive oxygen species (ROS) production was measured using the Total ROS 
Detection Kit (Enzo Life Sciences). Cells plated in a 96-well plate were incubated for 1 
hour at 37° C with 5 uM oxidative stress detection reagent. The cells were then washed 
twice with HBSS and intoxicated in HBSS. Toxin-treated cells were incubated at 37° C 
for 22 hours and fluorescence was read on a BioTek Synergy 4 plate reader. Relative 
ROS production was determined by setting fluorescence from mock-treated cells to 1 
and dividing treated cell fluorescence by the mock-treated fluorescence. 
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Results 
 
TcsH and TcsL induce cytotoxicity in endothelial cells. 
 Much of the previous work on TcsH and TcsL was done on cell lines that the 
toxins induced cell rounding in. In order to perform a study looking at the cytotoxicity 
and mechanisms of cell death induced by the C. sordellii toxins, I first needed to find a 
cell line that was able to effectively induce cell death. While TcsH, as well as TcdB of C. 
difficile, was induced cytotoxicity in HeLa cells, TcsL, as well as TcdA, was not able to 
Figure 2-1: Cytotoxicity in HeLa cells. HeLa cells were treated with TcsH, TcsL, 
TcdA, and TcdB over a range of concentrations.  Cell viability was determined by 
CellTiterGLO luciferase 2 (A), 8 (B), 24 (C), and 48 hours (D) after intoxication.  
Relative viability was calculated dividing the signal from intoxicated cells by the 
signal from those that were mock treated and averaging across three biological 
replicates.    
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induce noticeable cytotoxicity (Figure 2-1). Previous work in our lab by Nicole Chumbler 
(unpublished) has shown that TcdA is able to cause cytotoxicity in immorto-mouse 
derived epithelial cells (YAMC) which are conditionally immortalized at 33° C. I obtained 
an endothelial cell line derived from the same immorto-mouse, mPMVECs. When the 
mPMVECs were intoxicated, the toxins were able to induce cytotoxicity (Figure 2-2). 
Interestingly, both TcsH and TcdB saw induction of cytotoxicity at the highest 
concentrations as early as two hours after intoxication, while TcsL and TcdA did not 
show significant cell death until 24 hours. This was the first suggestion that the 
homology between TcsH/TcdA and TcsL/TcdB may not be consistent with which toxins 
act more similarly on cells.  
 
Apoptosis or necrosis induced by TcsH and TcsL. 
 Despite the high homology seen between TcsH and TcdA and between TcsL and 
TcdB, the cytotoxicity induced in cells does not seem to be similar in the time frame and 
extent of cytotoxicity. It appears that TcsH induces cytotoxicity in a time frame and 
severity more similar to TcdB while TcsL induces cytotoxicity more similar to TcdA. 
While it has been reported previously that TcsL induces cytotoxicity through apoptosis, 
it has not been extensively shown how TcsH causes cytotoxicity (124, 139). Recently, 
our lab has shown that at higher concentrations TcdB induces a necrotic cell death in 
cells while TcdA induces apoptosis (82, 141). While apoptosis relies on activation of 
caspases 3 and 7, necrosis is marked by an increase in reactive oxygen species (ROS) 
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in cells and the detection of lactate dehydrogenase outside the cell (82, 152, 153). 
Because of the high sequence homology between the C. sordellii and C. difficile toxins, 
and the similarity in cytotoxicity observed above, I decided to look for the ability of TcsH 
and TcsL to induce necrosis or apoptosis. 
 Lactate dehydrogenase (LDH) is a molecule that is typically found solubilized in 
the cytoplasm of cells. When the cell undergoes necrosis and loses membrane integrity, 
the cytoplasmic LDH is released and can be detected in the extracellular media (154). 
To determine whether TcsH or TcsL induce necrotic cell death, LDH release was 
Figure 2-2: Cytotoxicity in mPMVECs. mPMVEC cells were treated with TcsH, 
TcsL, TcdA, and TcdB over a range of concentrations.  Cell viability was determined 
by CellTiterGLO luciferase 2 (A), 8 (B), 24 (C), and 48 hours (D) after intoxication.  
Relative viability was calculated by dividing the signal from intoxicated cells by the 
signal from those that were mock treated and averaging across three biological 
replicates. Error bars represent standard deviation of the mean across three 
replicates. 
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measured in mPMVEC cells. Over a time-course of 7 hours, the amount of LDH 
released increased for cells treated with TcsH, similar to that seen for cells treated with 
TcdB (Figure 2-3). 
 An assay was also performed by Nicole Chumbler with TcsH and TcsL to look for 
the activation of caspase activity in epithelial YAMC cells. During apoptosis,  caspases 
3 and 7 are activated by cleavage of the pro-caspase forms (155) and then are able to 
disrupt downstream signaling pathways. To measure whether apoptosis or necrosis is 
induced, Nicole treated cells with TcsH and TcsL as well as TcdA and TcdB and 
measured the activity of caspases 3 and 7. Twelve hours after intoxication, Nicole 
measured the relative caspase activity based on the fluorescent signal from treated 
Figure 2-3: TcsH induces LDH release in endothelial cells. mPMVEC cells were 
treated with 10 nM TcsH, TcsL, TcdA, and TcdB.  LDH release was measured by 
luminescence on a plate reader every hour for 7 hours. Relative LDH release was 
calculated by dividing the luminescence from intoxicated cells by the signal from 
those that were mock treated and averaging across three biological replicates. 
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cells. TcsL shows a concentration dependent increase in caspase activation in cells, 
similar to apoptosis-inducing TcdA (Figure 2-4). The levels of TcsH-induced caspase 
activation did not change as the concentration of toxin changed and neither did the 
necrosis-inducing TcdB. This further suggests that TcsH induces a necrotic cell death 
similar to TcdB, while TcsL induces apoptosis like TcdA as has been reported in the 
literature. 
 
Signaling events induced by TcsH and TcsL intoxication. 
 It has been shown that certain stresses and signals produced by cells can turn 
on the pathways leading to necrosis, one of which is the production of ROS (153). Work 
Figure 2-4: TcsL induces caspase activation. YAMC cells were treated with TcsH, 
TcsL, TcdA, and TcdB at various concentrations.  Caspase activation was measured 
by fluorescence on a plate reader 12 hours post-intoxication. Relative caspase 
activation was calculated by dividing the fluorescence from intoxicated cells by the 
signal from those that were mock treated and averaging across three biological 
replicates. 
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from our lab has shown that ROS production is an important early step in the necrotic 
cell death induced by TcdB (141). Data also shows intracellular calcium release is 
increased as part of the events triggering and sustaining a necrotic response and the 
calcium increase occurs simultaneously with increased ROS production, although it is 
not yet clear which increases first (Farrow, unpublished). 
 Increased levels of intracellular calcium have been associated with increased cell 
death and necrosis (156, 157). Melissa Farrow from our lab has also seen a release of 
intracellular calcium that occurs rapidly after TcdB intoxication and increases in time as 
the cells undergo necrosis. To understand whether TcsH may be inducing a similar 
intracellular calcium signaling to cause necrosis I assayed for intracellular calcium levels 
in endothelial cells. When endothelial cells were treated with higher concentrations of 
TcsH, a spike in intracellular calcium was observed, similar to TcdB-induced calcium 
levels, which reached a maximum by four hours (Figure 2-5). Lower concentrations of 
Figure 2-5: TcsH induces intracellular calcium release. mPMVEC cells were 
treated with TcsH, TcsL, TcdA, and TcdB at 10 nM (A) and 0.1 nM (B).  Intracellular 
calcium was measured by fluorescence on a plate reader over a course of 14 hours. 
Relative intracellular calcium release was calculated by dividing the fluorescence 
from intoxicated cells by the signal from those that were mock treated and averaging 
across three biological replicates. 
B A 
 51 
TcsH were unable to induce a detectable increase of intracellular calcium, while TcdB 
was still able to induce a calcium increase at lower concentrations. This suggests that 
TcsH may induce necrosis through an intracellular calcium signaling pathway, but that 
TcsH is less potent than TcdB at inducing necrosis through this mechanism. 
 The production of reactive oxygen species (ROS) is also a signaling event that 
can lead to necrosis following cellular stress (153). TcdB-induced necrosis is dependent 
on ROS production from the NADPH oxidase (141). I tested for ROS production in 
endothelial cells to determine if TcsH induced necrosis through a ROS-dependent 
mechanism as well. When endothelial cells were treated with TcsH and TcsL, as well as 
TcdA and TcdB, a ROS response was seen in cells treated with 100 nM of both TcsH 
and TcsL (Figure 2-6). Interestingly, TcsL had the most robust ROS production, similar 
Figure 2-6: ROS induction by TcsH and TcsL. mPMVEC cells were treated with 
TcsH, TcsL, TcdA, and TcdB at various concentrations and H2O2. Reactive oxygen 
species production was measured by fluorescence on a plate reader 22 hours after 
intoxication. Relative ROS production was calculated by dividing the fluorescence 
from intoxicated cells by the signal from those that were mock treated and averaging 
across three biological replicates. 
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to the H2O2 positive control. TcdB, which induces ROS in epithelial cells, did not induce 
detectable ROS production in our assay using endothelial cells. This suggests that one 
or more components involved in TcdB-induced ROS are not present or different in 
endothelial cells. It also suggests ROS may not play the same role for C. sordellii toxins 
because TcsL is able to induce a robust ROS response but does not induce necrosis. 
 
Discussion 
 
 The purpose of this study was to determine the mechanism of cell death induced 
in cells by TcsH and TcsL and to compare to the homologues TcdA and TcdB of C. 
difficile. Based on the high structural and sequence identity between TcsH and TcdA 
and between TcsL and TcdB one could expect that the mechanisms of each toxin to be 
similar to the mechanism induced by their homologue. When a standard lab cell line, 
HeLa cells, were treated with TcsH and TcsL, they induced differing levels of 
cytotoxicity (Figure 2-1). Neither TcsL nor TcdA were able to induce cell death in HeLa 
cells, while cell rounding was observed. When endothelial cells were used that TcsL 
and TcdA could induce cytotoxicity in, TcsH was able to induce cell death at higher 
concentrations and in a short amount of time, which was similar to TcdB in both speed 
of cell death induction and that cytotoxicity was seen at the higher concentrations. 
Recent work has shown that TcdB is able to induce necrosis at higher 
concentrations, separate from the apoptosis that it has been attributed to causing (82, 
141). I wanted to see whether TcsH could also induce necrosis based on similarities 
seen between the levels and speed of cytotoxicity induced by TcdB. Endothelial cells 
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were treated with TcsH and TcdB, as well as TcsL and TcdA and the cells were 
assayed for LDH release and caspase activation, markers representative of necrotic 
and apoptotic cell death. TcsH intoxication induced LDH release at higher 
concentrations showing that TcsH leads to necrotic cell death in treated cells, similar to 
TcdB. Conversely, TcsL treated cells showed caspase activation supporting previous 
literature reports of TcsL inducing apoptotic cell death.  
I further looked into signaling events that have been shown to be involved in cell 
death, and have been shown to be present during TcdB-induced necrosis (141). 
Intracellular calcium release was induced when cell were treated with TcdA and TcdB at 
higher concentrations, although TcdB was able to induce a calcium response to lower 
concentrations than TcsH (0.1 nM). This suggests that although calcium release may be 
an important step in the necrotic death seen in both TcsH and TcdB, that TcdB is more 
potent at inducing both intracellular calcium release as well as necrosis at lower 
Table 2-1: Protein sequence identity between toxin domains. Protein sequences 
for TcdA and TcdB from C. difficile strain 10643 and TcsH and TcsL from C. sordellii 
were compared by Protein BLAST. The values shown indicate the amino acid 
sequence identity between each of the large clostridial toxins of each of the four 
individual domains: glucosyltransferase (GTD), autoprocessing, translocation, and 
CROPs domains. 
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concentrations. However, ROS production was seen in both TcsH- and TcsL-treated 
endothelial cells while TcdA and TcdB were not observed to produce ROS. The ROS 
production was more robust after TcsL-intoxication even though TcsL induced an 
apoptotic cell death. This suggests that ROS production in endothelial cells may be a 
separate event from induction of necrosis because TcdB did not induce ROS production 
in endothelial cells and TcsL, which induces apoptosis, produced the highest ROS 
response. 
The necrosis induced by TcsH similarly to TcdB and the TcsL-induced apoptosis 
similar to TcdA shows interesting similarity between the large clostridial toxins. Based 
simply on sequence and structural homology, TcsL would be expected to induce 
necrosis similar to TcdB at higher concentrations because they share the highest 
homology and TcsH would be expected to induce apoptosis like TcdA. These results 
show that while the large clostridial toxin family share many characteristics, such as 
glucosylation of GTPases and overall structural arrangement, the details of intoxication 
cannot be assumed based on homology to other toxins. Even when we look at the 
homology between each domain of the toxins, the homology remains consistent and 
highest between TcsH and TcdA and between TcsL and TcdB (Table 2-1). The lack of 
large differences in specific domains suggests that the differences in toxin-induced cell 
death are not the result of large, obvious differences in structure and amino acid 
sequence and that the differences between toxins is more nuanced. This shows how 
important it is for research in large clostridial toxins to study each toxin individually and 
to thoroughly investigate the possible similarities seen between large clostridial toxins, 
particularly those of C. sordellii and C. difficile.  
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CHAPTER III 
 
CLOSTRIDIUM SORDELLII LETHAL TOXIN AUTOPROCESSING AND MEMBRANE 
LOCALIZATION ACTIVITIES DRIVE GTPASE GLUCOSYLATION PROFILES IN 
ENDOTHELIAL STUDIES 
 
Introduction 
 
 Clostridium sordellii is a Gram-positive, spore-forming anaerobic bacterium that 
causes infections in humans and livestock (31). In humans, the bacteria enter at sites of 
soft tissue trauma and cause infections that lead to gas gangrene, sepsis, and, in up to 
70% of cases, death (2, 10, 20, 23). C. sordellii produces two major toxins, the 
hemorrhagic toxin (TcsH) and the lethal toxin (TcsL), which are considered the major 
virulence factors in disease (4, 5). First, animals that are injected with purified toxins 
develop symptoms that mimic the symptoms of C. sordellii infection (4, 48). Second, 
antibodies that target TcsL and TcsH can protect against tissue damage (6, 7). As a 
toxin mediated disease, there is therefore interest in understanding the molecular 
mechanism of toxin action, especially that of TcsL since not all clinical isolates contain 
TcsH (28). 
 While much of what we understand about TcsH and TcsL mechanism comes 
from analogy to the homologous TcdA and TcdB toxins from C. difficile, there are 
several reports validating the functional similarities.  Toxin activity relies upon binding to 
receptor(s) on the cell surface and clathrin-mediated endocytosis into the host cell (69).  
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Maturation of the endosome causes a conformational change in the pore-forming 
domain of TcsL causing it to form a pore in the endosomal membrane (71, 73).  The 
autoprocessing domain is activated by host inositol hexakisphosphate and cleaves the 
GTD (77, 81, 86, 87), presumably, to permit access to substrates residing at the plasma 
membrane.  The GTD glucosylates small GTPases, predominately Rac, Ras, Ral, and 
Rap (85, 90, 158).  The glucosylation leads to cytoskeletal rearrangement and rounding 
of the cells and also causes the induction of apoptosis (139, 150, 159, 160). 
 Previous studies have investigated the different roles of host GTPases in the 
cellular response to intoxication, and show that glucosylation of H, K, and NRas lead to 
the apoptotic cell death seen in cells by causing cell cycle arrest (123, 124, 161).  
Studies have also shown that Rac1 glucosylation drives a change in cell morphology 
through actin cytoskeletal rearrangement causing the cytopathic effects upon cells 
(162).  While work has been done to understand the relationship between specific 
GTPase glucosylation and the cellular effects induced by TcsL, an in-depth look at the 
role of the toxin functional activities in the context of cellular intoxication has not been 
reported. We have introduced mutations into TcsL to inhibit the glucosyltransferase and 
autoprocessing enzymatic functions and have studied the changes these mutations 
have on lung endothelial cells. 
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Methods 
 
Toxin cloning, expression, and purification: 
TcsL was amplified from the JGS6382 strain of C. sordellii and inserted into a 
BMEG20 vector (MoBiTec) using BsrGI/KpnI restriction digest sites in the vector as 
reported previously (81). Point mutations were introduced into the glucosyltransferase 
domain (F17N, R18A, D286N, and D288N) and autoprocessing domain (C698A) from 
the wild-type recombinant TcsL sequence using a QuikChange mutagenesis protocol. 
Construct names and primers used are found in the supplement (Table 1). Recombinant 
toxins were expressed in Bacillus megaterium using 35 mL of overnight culture seeded 
into 1 L of LB. Expression of toxin was induced at an OD600 of roughly 0.5 with 5 g D-
xylose and grown for 4 hours at 37° C with shaking at 220 rpm. The cells were pelleted 
and resuspended in lysis buffer (20 mM KPi pH 7, 500 mM NaCl, DNase, and protease 
inhibitors (Sigma)). The bacteria were passed through an Emulsiflex for lysis and 
centrifugation performed at 48,000 g for 30 min. Supernatants were run over Ni-affinity, 
anion exchange with a gradient from 20 mM Tris pH 8 to 20 mM Tris pH 8, 600 mM 
NaCl, and Superdex 200 size exclusion columns, and toxins eluted in 20 mM HEPES, 
pH 7, 50 mM NaCl.  
Native TcsL was purified from C. sordellii strain JGS6382 obtained from David 
Aronoff (Vanderbilt University). Expression and purification was done as previously 
described (82). 
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Cell culture: 
Conditionally immortalized murine pulmonary microvascular endothelial cells 
(mPMVECs) were obtained from the laboratory of Ambra Pozzi (Vanderbilt University).  
The cells were grown at 33° C using EGM-2 (Lonza) supplemented with 10 ng/mL IFN-γ 
in 5% CO2. For use, mPMVECs were transferred to 37° C for overnight growth in EGM-
2 media without IFN-γ. 
 
Viability assays: 
mPMVECs were plated at 2,500 cells/well in black wall 96-well plates. The cells 
were treated with toxin the following day and incubated at 37° C in 5% CO2 for either 24 
or 48 hours.  After incubation with toxin, viability was assessed by measuring the 
amount of ATP present by addition of CellTiterGLO (Promega), and the luminescence 
read using a BioTek Synergy 4 plate reader. Relative viability was calculated by setting 
the mock treated sample readings as representing 100% viability. 
 
Western blot analysis: 
Cell lysates were prepared from mPMVECs plated at 200,000 cells/mL in 10 cm 
dishes the day prior.  Cells were intoxicated with 10 nM toxin and incubated at 37° for 0, 
1, 2, and 3 hours before manual lifting from the dish. Cells were washed and 
resuspended in lysis buffer (250 mM sucrose, 10 mM Tris pH 7.4, 3 mM imidazole) and 
passed through a 27G needle 25 times.  The lysates clarified by centrifugation.  
Samples were run on SDS-PAGE gels (Bio-Rad) and transferred to PVDF for Western 
analysis. Blots were probed with antibodies for unmodified Rac1 (BD, 610651), total 
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Rac1 (Millipore, clone 23A8), unmodified Ras (Abcam, ab52939), total HRas (Santa 
Cruz, sc-520), and GAPDH (Santa Cruz, sc-25778). HRP-conjugated anti-mouse and 
anti-rabbit antibodies (Cell Signaling, 7076 and 7074, respectively) were applied as 
secondary antibodies, and the blots were visualized using Pierce ECL Western Blotting 
Substrate (Thermo) and exposure to film. Film was scanned using the Odyssey Licor 
Imaging System and analyzed using Image Studio Lite. 
 
In vitro cleavage assay: 
200 nM TcsL and TcsL C698A were placed into MES buffer (pH 7) containing 
100 mM DTT with or without 5 mM IP6. The reactions were placed at 37° C for 0, 30, 
60, 90, and 120 minutes. The reactions were stopped by adding loading buffer and 
boiling. Samples were separated by SDS-PAGE gels and stained by SimplyBlue 
SafeStain Coomassie (ThermoFisher). 
 
In vitro glucosyltransferase assay: 
TcsL and TcsL C698A were incubated in buffer containing 50 mM HEPES, 100 
mM KCl, 1 mM MnCl2, 2 mM MgCl2, 0.1 mg/mL BSA (pH 7.5) with 24 uM UDP-
[14C]glucose (250 mCi/mmol, PerkinElmer) and 2 uM GST-tagged Rac1 or HRas for 1 
hour at 37° C. Reactions were stopped by adding loading buffer and boiling. Samples 
were separated by SDS-PAGE, and the dried gels were imaged using a Typhoon FLA 
7000 phosphoimaging scanner. 
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Liposome binding assay: 
Liposomes were prepared using 30% DOPE, 20% cholesterol, 20% egg PC, and 
30% brain PS (Avanti Polar Lipids) by combining lipid solutions in chloroform and dried 
by nitrogen gas and vacuum. The dried lipids were resuspended to 10 mM final 
concentration in 20 mM HEPES, pH 7.5, 100 mM KCl and freeze-thawed. The lipids 
were then passed through an extruder using a 0.2 uM filter repeatedly. Toxin was 
cleaved using 2 uM toxin, 50 mM DTT, and 5 mM IP6 in 20 mM HEPES pH 7 buffer and 
incubated at 37° C for 2 hours. The cleaved toxin was dialyzed against 20 mM HEPES, 
pH 7.5, 100 mM KCl to remove IP6 and DTT. Liposome binding reactions were 
prepared using 3 mM liposomes and 0.5 uM dialyzed toxin incubated in 20 mM HEPES, 
pH 7.5, 100 mM KCL buffer containing 1 mM MgCl2 and 1 mM CaCl2 for 1 hour at 37° 
C. The reactions were separated by centrifugation at 436,000 g for 1 hour at 23° C. 
Pellets were resuspended in the same volume of buffer with 1% SDS added. Samples 
were separated by SDS-PAGE and stained by SimplyBlue SafeStain Coomassie 
(ThermoFisher). 
 
Statistics: 
Statistics were performed on our data using two-way ANOVA and p-values were 
determined using Dunnett’s multiple comparisons test on GraphPad Prism. 
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Results 
 
TcsL induces cytotoxicity in mPMVEC cells. 
TcsL cytotoxicity is driven by glucosylation of Ras, and many Ras related 
pathways are mutated in standard cell lines to induce immortality. Much of the work 
done to study the impact of TcsL has used either transformed cell lines or cell lines that 
do not accurately represent the tissue specificity shown during C. sordellii infections. C. 
sordellii infection leads to edema and hypotension, and TcsL induces vascular 
permeability in the lungs of mice (48). This suggests that lung endothelial cells are a 
physiologically relevant model for studies of TcsL function. We chose conditionally 
immortalized murine pulmonary microvascular endothelial cells (mPMVECs), which 
behave similarly to primary cells when grown at 37° C but are permissive for expression 
of the SV40 large T antigen at 33° C (163). We used a recombinant system to allow for 
expression and purification of TcsL with specific point mutations (69, 81). Cells were 
treated with TcsL across a range of concentrations at both the permissive temperature 
(33° C) and the non-permissive temperature (37° C). TcsL induced significantly higher 
levels of cytotoxicity at 37° C (Figure 3-1A). A comparison between recombinant TcsL 
and TcsL purified from C. sordellii indicates that both forms of TcsL induce similar 
effects on endothelial cells with no statistical difference in cytotoxicity levels. (Figure 3-
1B). 
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Figure 3-1: mPMVECs as a model to study cytotoxicity. (A) Murine pulmonary 
microvascular endothelial cells (mPMVECs) were incubated at 33° or 37° C and 
treated with TcsL over a range of concentrations.  Cell viability was determined by 
CellTiterGLO luciferase 24 hours after intoxication.  (B) The dose responses for 
native and recombinant TcsL were identical. Toxins were incubated with mPMVECs 
for 24 hours at 37° C. Relative viability was calculated dividing the signal from 
intoxicated cells by the signal from those that were mock treated and averaging 
across three biological replicates.  Error bars represent standard error of the mean. 
**** shows p-values <0.0001. 
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TcsL autoprocessing and glucosyltransferase activities are important for cytotoxicity. 
To determine the importance of the enzymatic activities of TcsL, mutations were 
introduced into the active sites of the GTD and the autoprocessing domain.  The 
glucosyltransferase activity was ablated by the introduction of D286N and D288N 
mutations (DxD), and the autoprocessing activity was eliminated by introducing a 
C698A mutation (78, 81, 92) (Table 3-1, Figure 3-2). The endothelial cells were treated 
with TcsL as well as the glucosyltransferase and autoprocessing mutants (DxD and 
C698A, respectively). Cell viability was determined at 24 and 48 hours post-intoxication 
using CellTiterGLO. When cells were treated with glucosyltransferase-deficient TcsL, no 
cell death was seen except at the highest concentration tested (Figure 3-3). The 
autoprocessing mutant was attenuated but still induced cytotoxicity.  These findings 
Figure 3-2: TcsL C698A is deficient in autoprocessing ability. In vitro cleavage 
assay was performed for TcsL and TcsL C698A by placing in a reaction with IP6 and 
DTT at 37° for up to 120 minutes. The samples were separated on a SDS-PAGE gel 
and bands corresponding to cleaved GTD are seen in TcsL lanes but only uncleaved 
holotoxin is present in TcsL C698A samples. 
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suggest that glucosyltransferase activity is required for cytotoxicity while the 
autoprocessing activity is important but not required for induction of cell death.  
Plasmid 
Name 
Protein 
Expressed Primer Sequences Used 
pBL552 
TcsL in BMEG20 
vector 
  
  
pBL685 TcsL C698A 
5'-GTCTATAGAAATAAATTTACTAGGAGCTAATATGTTCAGCTATAACGTTAATG-3' 
5'-CATTAACGTTATAGCTGAACATATTAGCTCCTAGTAAATTTATTTCTATAGAC-3' 
pBL686 
TcsL D286N, 
D288N 
5'-GGTGGGGTATATTTAAATGTTAATATGTTACCAGGTATAC-3' 
5'-GTATACCTGGTAACATATTAACATTTAAATATACCCCACC-3' 
pBL691 TcsL R18A 
5'-GGCATATGTAAAATTTGCTATTCAAGAAGATGAGTACGTAGC-3' 
5'-GCTACGTACTCATCTTCTTGAATAGCAAATTTTACATATGCC-3' 
pBL692 TcsL F17N 
5'-GGCATATGTAAAAAATCGTATTCAAGAAGATGAGTACGTAGC-3' 
5'-GCTACGTACTCATCTTCTTGAATACGATTTTTTACATATGCC-3' 
pBL745 
TcsL F17N, 
R18A 
5'-GGCATATGTAAAAAATGCTATTCAAGAAGATGAGTACGTAGC-3' 
5'-GCTACGTACTCATCTTCTTGAATAGCATTTTTTACATATGCC-3' 
  
`pBL746 
TcsL F17N, 
R18A, C698A 
sequences above for pBL745 and pBL685 
  
 
 We next assayed the impact of enzyme mutation on the glucosylation of 
Rac1 and Ras GTPases in cells. We analyzed endothelial cell lysates that had been 
treated with 10 nM TcsL, TcsL DxD, and TcsL C698A. Cell lysates were analyzed by 
Western blots using Rac1 and Ras antibodies that are specific to unglucosylated 
GTPase (90, 124, 164). Once the Rac1 and Ras are modified by TcsL, the antibody can 
no longer recognize its epitope, and the signal is lost.  The cells that were treated with 
TcsL showed modification after one hour, and glucosylation of both GTPases was 
nearly complete by 2 hours (Figure 3-4). When TcsL DxD was used to intoxicate cells, 
the loss of the glucosyltransferase activity rendered the mutant unable to glucosylate 
Table 3-1: Plasmid information and primer sequences for TcsL and TcsL 
mutations 
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both Rac1 and Ras. Interestingly, TcsL C698A was able to quickly glucosylate Rac1, 
similar to wildtype TcsL, but was attenuated in its ability to glucosylate Ras GTPases. 
The introduction of the autoprocessing mutation did not inhibit the ability of Rac1 or 
Figure 3-3: TcsL autoprocessing and glucosyltransferase mutants are 
impaired in cytotoxicity. Endothelial cells were treated with TcsL, 
glucosyltransferase deficient TcsL (DxD), or autoprocessing deficient TcsL (C698A) 
over a range of concentrations. Cell viability was determined by GLO luciferase 24 
hours (A) and 48 hours (B) after intoxication. Relative viability was calculated by 
dividing the signal from intoxicated cells by the signal from those that were mock 
treated and averaging across three biological replicates. Error bars represent 
standard error of the mean. *** shows p-values <0.001. 
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HRas glucosylation as shown in vitro compared to wild-type TcsL (Figure 3-5). The 
difference in Rac1 and Ras glucosylation when the autoprocessing activity was ablated 
suggests that there is a localization difference for Rac1 and Ras.  
 
 
Figure 3-4: Kinetics of Rac1 versus Ras glucosylation differ when cells are 
treated with TcsL autoprocessing mutant. Endothelial cells were treated with 10 
nM TcsL, TcsL DxD, TcsL C698A or PBS only.  The cells were incubated for 0, 1, 2, 
or 3 hours before lysis. (A) Lysate supernatants were analyzed by Western blot 
using antibodies for unglucosylated Rac and Ras, total Rac, total HRas, and 
GAPDH. Quantification was performed for Rac (B) and Ras (C) signal relative to 
PBS-treated sample at 0 hours. Error bars show standard error for the mean of four 
replicates. 
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Mutations in the GTD membrane localization domain inhibit TcsL cytotoxicity. 
 Previous reports have identified a membrane localization domain (MLD) on the 
GTD that is involved in the localization of the GTD to the plasma membrane (143, 144). 
To test the importance of the MLD in TcsL cytotoxicity, F17N and R18A mutations were 
created as well as a double mutant (F17N, R18A). These residues are found on the 
surface of the MLD and have been previously implicated in membrane localization 
(Figure 3-6) (144), which we also saw when the mutants were tested in a liposome 
binding assay (Figure 3-7). A triple mutant (F17N, R18A, C698A) was also created to 
determine the impact of both autoprocessing and MLD mutations on cytotoxicity. 
Endothelial cells were treated with TcsL and TcsL MLD mutants, and cytotoxicity was 
assessed. Relative to treatments with wild-type TcsL, cytotoxicity was significantly 
attenuated when cells were treated with the MLD mutants (Figure 3-8). The level of 
attenuation for TcsL MLD mutants is similar to the attenuation of TcsL C698A and 
suggests that TcsL cytotoxicity is dependent upon GTD localization to the cell 
membrane. 
Figure 3-5: Autoprocessing mutation does not alter glucosylation. 
Recombinantly expressed GST-Rac1 and GST-HRas were glucosylated using TcsL 
and TcsL C698A in the presence of UDP-[14C]glucose for 1 hour. The protein gels 
were imaged and bands represent glucosylated GTPase. 
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Figure 3-6: TcsL MLD location and mutations. A) Electrostatic maps of the GTD 
of TcdB and TcsL are shown. At the N-terminus, boxed in red, is the location of the 
conserved membrane localization domain. The homology between the TcsL MLD 
with TcdB can be seen. Positively charged residues are shown in blue and 
negatively charged residues are shown in red. Adapted from Pruitt et al. (171). B) A 
zoomed image of the TcsL MLD with the amino acids targeted for mutagenesis (F17 
and R18) are shown at the bottom of the structure. 
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 To understand how MLD mutations affect the mechanism of cellular response, 
we next assayed the glucosylation of Rac1 and Ras by TcsL MLD mutants. Cell lysates 
were obtained from endothelial cells treated with TcsL and TcsL MLD mutants and 
analyzed by Western blot for Rac1 and Ras glucosylation. While TcsL was able to 
quickly glucosylate Rac1 and Ras, the MLD mutants were attenuated in capacity to 
glucosylate substrates in the cell (Figure 3-9). Both TcsL F17N and TcsL R18A were 
Figure 3-7: MLD mutants disrupt lipid binding. TcsL and TcsL mutants were 
combined with liposomes and after incubation the bound toxin was pelleted. The gel 
(bottom) shows both supernatant and pellet fractions for each toxin and is 
representative of three separate experiments. The relative values show that the 
bound toxin level decreases when membrane localization mutations are introduced. * 
shows p-value <0.05. 
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delayed in their glucosylation of Rac1 and Ras, and the double mutant, TcsL F17N 
R18A, was the most attenuated in its glucosylation of Rac1 and Ras. The triple mutant 
(F17N, R18A, C698A) was also inhibited in both Rac1 and Ras glucosylation. These 
observations indicate that the MLD interaction with the membrane is important for the 
Figure 3-8: TcsL membrane localization domain is important for cytotoxicity. 
Endothelial cells were treated with various concentrations of TcsL, TcsL membrane 
localization mutants (F17N, R18A, and F17N R18A), TcsL C698A, or the triple 
mutant TcsL F17N R18A C698A (C+F+R). Cell viability was determined by GLO 
luciferase 24 hours (A) and 48 hours (B) after intoxication.  Relative viability was 
calculated by comparing the signal to cells that were mock treated and represents 
the average of three replicates.  Error bars represent standard error of the mean. **** 
shows p-values <0.0001. 
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glucosylation of both Rac1 and Ras and that the MLD mutation prevents the 
autoprocessing-deficient TcsL from efficiently glucosylating Rac1. 
 
Discussion 
 
 The purpose of our study was to understand the impact of the different TcsL 
enzymatic activities in the context of lung endothelial cells. Although many cell lines 
have been used in the study of TcsL-induced effects, we wanted to find a cell line that 
Figure 3-9: Membrane localization domain is required for efficient Rac 
modification. Endothelial cells were treated with 10 nM TcsL, TcsL F17N, TcsL 
R18A, TcsL F17N+R18A, or TcsL C698A+F17N+R18A for 0, 1, 2, or 3 hours.  Cells 
were lysed using detergent-free lysis and supernatants were stained for unmodified 
Rac and unmodified Ras GTPase (A). The signals relative to untreated samples 
were quantified for unmodified Rac (B) and unmodified Ras (C) and averaged across 
three replicates. Error bars represent standard error of the mean. 
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would be a good, physiologically accurate model for the effects seen during infection. 
Symptoms seen commonly in C. sordellii infection are edema, hypotension, and multi-
organ failure, indicating that the toxins act strongly upon host microvasculature. Our use 
of conditionally immortalized murine pulmonary microvascular endothelial cells allowed 
us to induce a primary cell-like state that removed the potential interference of common 
mutations associated with immortalization.  Figure 3-1 shows that TcsL is a potent 
cytotoxin in these cells and, thus, allowed us to assess the impact of enzymatic 
activities in the cell death mechanism. 
 When endothelial cells were treated with TcsL and the DxD and C698A mutants, 
we saw cytotoxicity was inhibited for the glucosyltransferase mutant and impaired in the 
autoprocessing mutant. The inhibition of cytotoxicity when treating cells with TcsL DxD 
supports previous research showing that glucosylation of the host cell GTPases leads to 
arrest of the cell cycle and induction of apoptosis (123). The decrease in cytotoxicity 
seen with TcsL C698A suggests that the autoprocessing activity is important in TcsL 
cytotoxicity (Figure 3-3).  
Previous studies investigating the role of autoprocessing in the C. difficile toxins 
suggest that preventing GTD release through inactivation of the autoprocessing activity 
has only modest effects on cytopathic responses (165), and, in the case of TcdB, no 
impact on toxin-induced necrosis (82).  The observations beg the question, why has the 
autoprocessing activity been retained in this family of toxins?  A key difference between 
TcsL and the C. difficile toxins is that TcsL is more active in the modification of Ras 
GTPases (90, 164), and Ras inactivation has been linked to TcsL-induced cell death 
(123). We therefore assayed whether TcsL and the TcsL C698A mutant were capable 
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of modifying both Rac and Ras. The experiments in Figure 3-3 reveal that while 
autoprocessing is not required for the modification of Rac, it is important for the efficient 
modification of Ras. 
 The differential ability to glucosylate the GTPases when the GTD is not cleaved 
from the holotoxin suggests a difference in the localization of Rac and Ras GTPases. It 
has been reported that Rac cycles to the endosomes where it is activated before 
trafficking back to the membrane (126). TcsL C698A does not release the GTD, and it 
remains bound to the endosome. The GTD may then encounter Rac that has been 
trafficked to the endosome for activation. Ras GTPases, however, are trafficked to and 
found in abundance at the plasma membrane after translation (133). We therefore 
propose that the GTD that remains tethered to the endosome does not immediately 
encounter and glucosylate Ras proteins. We propose that the slow Ras glucosylation is 
due to endosomal membranes, with the tethered GTD, recycling back to the cell 
surface.  The delay in Ras glucosylation is enough to cause the decrease in cytotoxicity. 
 Previous studies have identified a MLD on the TcsL GTD that is conserved 
across all large clostridial toxins and important in membrane localization. The MLD may 
be important for GTD to insert into the plasma membrane and help tether it to the 
membrane (145, 146). We looked at the impact of MLD point mutations on both 
cytotoxicity (Figure 3-8) and the glucosylation of host GTPases (Figure 3-9). Our work 
shows that the introduction of MLD mutations inhibits the ability to induce cytotoxicity 
and delays the glucosylation of both Rac and Ras GTPases, supporting the importance 
of the MLD in tethering GTD to the cell membrane where it can interact with and 
glucosylate the GTPases. Interestingly, when we combined the MLD mutations with the 
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autoprocessing mutation, we saw a decrease in cytotoxic ability as well as glucosylation 
of both Rac and Ras. While TcsL C698A was able to efficiently glucosylate Rac, the 
loss of efficient Rac glucosylation with the introduction of MLD mutations suggests that 
it is not enough for the GTD to be tethered to the endosome but also relies on the ability 
of the GTD to interact with the endosomal membrane through the MLD. 
 Our studies have shown the impact of mutating the enzymatic domains of TcsL. 
While the glucosyltransferase activity is needed for Rac modification and cytotoxicity, 
autoprocessing-deficient TcsL is impaired in cytotoxicity but efficient in its modification 
of Rac. We also show that the interaction with the cell membrane, not just proximity, is 
needed for efficient glucosylation of GTPases. The increased understanding of each 
toxin domain during host intoxication provides a foundation for more targeted 
approaches to study toxin-induced cellular events.  
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
 TcsH and TcsL are the primary virulence factors of C. sordellii, whose infections 
lead to serious illness and have a high mortality rate. Due to the fact that C. sordellii 
infection is a toxin-mediated disease, a better understanding of TcsH and TcsL will help 
to understand the disease and provide us further insights into potential ways to combat 
or prevent serious infections. Much of our understanding of the functions and 
mechanisms of action for C. sordellii toxins, particularly TcsH, has been derived from 
studies of homologous LCTs. In my thesis work, I have shown that TcsH and TcsL 
induce cell death by different mechanisms and that TcsL glucosylation depends on 
autoprocessing and membrane localization. 
 In Chapter II, I have presented work comparing the cell death mechanisms 
induced by TcsH and TcsL, and compared these to the cytotoxicity induced by TcdA 
and TcdB of C. difficile. I have shown that TcsL induces apoptosis based on the 
activation of caspases and lack of necrotic death markers, which supports what has 
been shown previously in the literature. TcsH induces a necrotic cell death at higher 
toxin concentrations that is marked by LDH release and onset of cytotoxicity seen two 
hours after intoxication. After looking for common signaling events that occur during 
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many cell death pathways, I show that TcsH induces intracellular calcium release at 
necrotic concentrations and that both TcsH and TcsL induce ROS production. 
 This work shows the differences between C. sordellii toxins and their 
homologues from C. difficile. TcsH/TcdA and TcsL/TcdB share high sequence and 
structural homology which may suggest that the toxins act in similar manners. However, 
the cell death mechanisms induced by the homologous toxins are different. TcsH 
induces a necrotic cell death at higher concentrations which is similar to what was seen 
and reported for TcdB, while both TcsL and TcdA induce apoptosis. Interestingly, TcsH 
induced intracellular calcium release and ROS production at high concentrations. In 
contrast, TcdB treated endothelial cells did not show evidence of ROS production. 
These data suggest that while TcsH and TcdB share some similarities in their necrosis 
induction, the mechanisms for each toxin are unique and differences exist despite the 
homology between the LCTs. 
 In Chapter III, I have shown work describing the importance of the enzymatic 
activities and membrane localization of TcsL. Introduction of point mutations to inhibit 
activity lead to the conclusion that TcsL cytotoxicity is dependent upon 
glucosyltransferase activity. I have also shown that autoprocessing activity is important 
but not necessary for TcsL-induced cytotoxicity. Ras glucosylation depends on 
autoprocessing of TcsL, while Rac glucosylation was found to be independent of 
autoprocessing. Further work showed that the MLD was important for the induction of 
cytotoxicity and MLD mutants displayed decreased in glucosylation activity in cells. 
 This work has helped us to increase our understanding of TcsL, one of the main 
virulence factors in C. sordellii infections. We built on our previous understanding of 
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LCT domains and enzymatic activities to determine which were important and what role 
they played during toxin-induced glucosylation and cytopathicity. Each enzymatic 
activity tested is important for cytotoxicity while autoprocessing is not required. 
Autoprocessing activity is also not necessary for Rac glucosylation but is important for 
Ras glucosylation, suggesting that differential localization of the TcsL GTD determines 
the glucosylation profile. The MLD was also shown to be important for glucosylation and 
cytotoxicity of TcsL by the introduction of mutations which decreased cytotoxicity and 
delayed glucosylation. By combining the autoprocessing and MLD mutants, I showed 
the MLD is important for interacting with the host membrane to facilitate glucosylation 
and that the MLD is not simply for GTD localization. 
 
Future Directions 
 
Determine mechanism of TcsH-induced necrosis 
 In Chapter II, I showed that TcsH is able to induce a necrotic cell death in 
endothelial cells at a high concentration. I also showed that TcsH induces an 
intracellular calcium release and low levels of ROS production as well. While this 
suggests that calcium and ROS signaling may play a role in TcsH-induced necrosis, I 
would like to look further into the mechanism driving necrosis in endothelial cells. I want 
to identify host factors that are important for TcsH-induced necrosis and determine what 
role they play in the signaling events that lead to cell death. To this point, no work has 
been done to determine the mechanism used by TcsH to induce cytotoxicity and any 
knowledge of the process would help to identify host factors, protein complexes, or 
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signaling pathways that can be targeted for therapeutics to reduce the toxin’s harmful 
effects during infection. 
 To determine the mechanism I would first look to identify host factors involved in 
the induction of necrosis. This can be done using several approaches: a siRNA screen 
and a CRISPR knockout screen. The siRNA screen would knockdown protein 
expression levels in the host cells to identify proteins conferring sensitivity to toxin-
induced necrosis, similar to what was done with TcdB in our lab. A CRISPR-knockout 
screen would be similar but would allow for the complete knockout of protein expression 
using the CRISPR-Cas system developed previously (166). 
 Once potential host proteins are identified, I can begin testing their role in TcsH-
induced necrosis. The first priority would be to confirm that they are important in 
necrosis by looking for changes in LDH release of TcsH-treated cells when the target 
protein is knocked down as well as to see whether the levels of activated caspases are 
altered. Once several proteins are identified, I can begin to create a pathway of 
signaling and interactions by removing components and testing for disrupted 
interactions and signaling events downstream. 
 The importance of the observed ROS and intracellular calcium in the induction of 
necrosis will also be evaluated. The ROS production can be inhibited by treating 
endothelial cells with compounds, such as tempol, DPI, ebselen, or NAC, that are 
known inhibitors (141). The decrease in ROS production can then be measured and the 
cells will be tested for a correlated decrease in necrosis that would support the 
importance of ROS production as a precursor in necrotic cell death. The same can be 
done using inhibitors of intracellular calcium release to test for the importance of 
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intracellular calcium signaling for TcsH-induced necrosis. To determine whether 
intracellular calcium release or ROS production provide signaling crosstalk, the levels of 
each can be tested under the same conditions to determine if a change in the levels of 
one alters the other. 
 
Determine the importance of TcsH enzymatic activities 
 Very little work has been done to this point to study TcsH and no in-depth work 
has been done looking at the importance and role of the enzymatic activities of the 
TcsH domains on intoxication. Similar to the work presented in Chapter III for TcsL, 
mutations can be introduced to inhibit the enzymatic activity of the glucosyltransferase 
and autoprocessing domains and the impact upon cytotoxicity and cytopathicity can be 
determined. Having an increased understanding of the importance of TcsH enzymatic 
activities can help to better understand the toxin and design the best inhibitors to 
prevent TcsH from damaging host tissues during C. sordellii infection. While the field 
currently holds that the activity of each domain is important for intoxication, the ability of 
TcsH to induce necrosis at higher concentrations similar to TcdB emphasizes a need to 
test the role of each enzymatic activity. Work from our lab has shown TcdB is able to 
induce cell death independent of autoprocessing or glucosyltransferase activity, 
suggesting these enzymatic activities may not be necessary in TcsH as well (82, 141). 
 Mutations will be introduced into recombinantly expressed TcsH that inhibit the 
autoprocessing activity (C700A) and glucosyltransferase activity (D285A D287A). 
Endothelial cells will be treated with the mutant toxins and compared with wild type 
TcsH looking for changes in glucosylation levels of Rac1 and the amount of cytotoxicity 
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induced. A shift in the ability of TcsH to induce necrosis, as well as a shift in the 
concentration of toxin required, could also be tested using the mutants by measuring 
changes in the levels of LDH release in cells. If TcsH does induce necrosis by a 
mechanism similar to TcdB, we would not expect to see a change in necrosis when the 
enzymatic activities are inhibited. 
 This work would help us to better understand the importance of the enzymatic 
activity and domains found in TcsH. By understanding which activities are important for 
the cytotoxicity and cytopathicity of TcsH, we can determine which toxin activities would 
be most effective to target and inhibit for therapeutic purposes and reduction of tissue 
damage observed during C. sordellii infection. The work would also help to increase our 
understanding of the similarities between the LCTs. If TcsH does not require its 
enzymatic activities to induce necrosis, similar to what has been observed for TcdB, it 
would support the idea that the necrotic mechanism and signaling pathways may be a 
conserved characteristic of LCTs and necrosis may be induced by other toxins but has 
not yet identified. 
 I initially started working on this future direction as part of my project but 
experienced difficulties recombinantly expressing TcsH. After experiencing differences 
in cytotoxicity between preparations of purified TcsH, it was noticed that TcsH from 
different preparations ran at slightly different sizes on a protein gel. I sequenced TcsH 
from several isolates of the toxin-expressing B. megaterium and found that deletions 
were present in most of the colonies. The mutations were localized to the CROPs 
region of TcsH and the location and length of the deletions was random. The deletions 
also occurred rapidly after the expression plasmid was transformed into B. megaterium, 
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making it difficult to consistently express full-length TcsH. Moving forward with a project 
relying on recombinant expression of TcsH and TcsH mutants would rely on developing 
a successful expression system. One possibility is to introduce recombination deletions 
into B. megaterium system that would prevent deletions from recombination events. 
Another possibility is to switch to expression using B. subtilis, which has recombination 
deficient strains available for expression. The drawback to this approach is that B. 
subtilis forms spores and the ability to do so would need to be removed prior to safe 
expression of TcsH in the laboratory. A third approach would be to engineer a codon-
optimized TcsH gene that would reduce the number of nucleotide repeats in the CROPs 
region and use codons that are more commonly expressed by B. megaterium. The 
sequence optimization would hopefully decrease the ability of the bacteria to perform 
recombination and allow them to more easily express the toxin. 
 
Identify TcsL and TcsH surface binding receptors 
 Research has shown that TcsH and TcsL enter cells through receptor-mediated 
endocytosis, but no work has identified the receptors for each toxin. Future work 
focused on identifying the cell surface receptors responsible for binding TcsH and TcsL 
would provide valuable information about the early entry and intoxication process for 
each toxin. Our lab has a siRNA library that can be used to knockdown genes in 
endothelial cells and changes in cytotoxicity can help identify potential toxin binding 
targets. Further screening to test changes in toxin binding can make use of fluorescently 
labeled toxin, either by direct labeling or the introduction of a fluorescent tag, to test for 
a decrease in binding ability by FLOW cytometry. Toxin receptors can also be validated 
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using binding competition assays including treatment of cells with antibodies against the 
cell receptor or pre-treatment of toxin with soluble domains or peptides from the 
potential receptors. 
 To further the understanding of the TcsH and TcsL receptors, work can also be 
done to identify the binding sites between toxin and receptor. Expression constructs can 
be generated for truncated TcsH and TcsL as well as individual toxin domains. These 
can be used in pull-down experiments combined with purified full-length receptors or 
truncated receptor constructs to narrow down the peptides required for a binding 
interaction between toxin and receptor. After narrowing down the binding site on each 
protein, structural studies can be done to identify the amino acids responsible for the 
binding interaction. Our lab regularly performs crystallography studies and determining 
the crystal structure of toxin bound to its receptor would allow for identification of precise 
amino acids involved in the interaction. 
The amino acids identified by crystallography as important for toxin binding would 
be tested by introducing point mutations both into the toxin and the receptor. The 
mutated toxin and receptor expression constructs can be tested by pull-down assays to 
determine if the binding efficiency is decreased. A FLOW cytometry-based binding 
assay can also be performed by treating cells with mutated toxin or treating cells that 
express mutated receptors and looking for a decrease in binding fluorescence of TcsH 
or TcsL. Another possible assay that our lab has recently utilized to confirm the 
importance of specific amino acids in the toxin-receptor binding interaction is to 
incorporate unnatural amino acids that can be photo-cross-linked to the binding partner 
(167). If the site of the unnatural amino acid is important for binding, after exposing a 
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mixture of receptor and toxin, a bound fragment at a higher molecular weight will be 
present on a protein gel. 
The identification of TcsH and TcsL receptors and the specific amino acids 
involved will allow for advances in treatment of C. sordellii infection. Knowing the exact 
binding epitopes for the toxins allows for the production of antibodies that can disrupt 
and block binding of the toxins. By blocking the interaction with receptors, the toxins’ 
damaging effects in host tissues can be decreased and hopefully provide healthcare 
workers more time to treat and control C. sordellii infections and ultimately lead to a 
decrease in the mortality rate. 
 
Identify compounds that inhibit TcsH and TcsL cytotoxicity 
 Another possible direction to pursue for TcsH and TcsL is the identification of 
chemical compounds that can inhibit cytotoxicity. As a toxin-mediated disease, the 
damage caused during C. sordellii infection can be greatly reduced and the survival rate 
increased if we can provide effective treatment to patients that inhibits TcsH and TcsL. 
To identify chemical compounds that can inhibit toxin-mediated cytotoxicity, we 
can make use of the Vanderbilt high-throughput core to screen chemical compounds for 
their ability to decrease TcsH and TcsL cytotoxicity. Compounds that decrease the cell 
death induced by the toxins can then be followed up to determine the toxin mechanism 
that is disrupted and inhibited. The compounds can be tested for their ability to inhibit 
cell entry and trafficking, autoprocessing, glucosylation, or another important step of 
intoxication. The compounds can also be studied to see if the chemical can be 
optimized for an increased inhibition and testing can also be done to determine the 
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safety of using the compound in a clinical setting. The compound can also be tested in 
an animal model of C. sordellii infection to determine the level of protection the 
compound can provide by inhibiting TcsH or TcsL. 
 
 Although we have learned a great deal already about TcsH and TcsL cytotoxicity 
in cells, there is still much to be studied. The knowledge gained from these studies will 
also help us to better understand LCTs and the range of activities and impacts they are 
responsible for in cells and tissue. An increased understanding of these toxins will be 
important for directing research and the development of more effective treatments for C. 
sordellii infections. 
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